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ABSTRACT
Nuclear Aurora-A kinase-induced hypoxia signaling drives dissemination and
metastasis in breast cancer.
Kristina M. Whately
Metastatic breast cancer causes the vast majority of cancer-associated deaths,
especially in triple negative breast cancers (TNBC). TNBC is still poorly understood and
has no effective treatment. Here we reveal that presence of Aurora-A Kinase (AURKA)
in the nucleus and metastatic dissemination are molecularly connected through HIF1
(Hypoxia induced factor-1) signaling. The nuclear AURKA in the complex with
constitutively expressed HIF-1β subunit activates transcription of “hypoxia induced
genes” under normoxic conditions (the phenomenon called pseudohypoxia) without
upregulation of oxygen-sensitive HIF-1α subunit. We uncover that AURKA preferentially
binds to and phosphorylates HIF-1β, and co-localizes with HIF complex on DNA. The
mass spectrometry analysis of AURKA complex further confirmed presence of CBP and
p300 along with other TFIIB/RNApol II components. Importantly, expression of multiple
HIF-dependent genes including migration/invasion, survival/death and stemness
induced by nuclear AURKA promote early cancer dissemination. These results indicate
that nuclear pool of AURKA, but not cytoplasmic, is a novel driver of early metastatic
dissemination. Analysis of clinical tumor specimens revealed a correlation between HIF1α and AURKA levels and an association of their co-expression to decreased patient
survival. Our results establish a mechanistic linkage between two key pathways in
cancer metastasis, identifying nuclear AURKA as a critical upstream regulator of HIF-1
transcription complex, and a target for anti-metastatic therapy.
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CHAPTER 1: Literature Review
Metastasis Overview
Metastatic disease is responsible for 90% of cancer-related deaths. Metastasis is
the process of cancer cells escaping their primary site and traveling through the body to a
different secondary site. The metastatic process consists of multiple steps: establishing a
pre-metastatic niche (PMN), invasion, intravasation, extravasation, and colonization (1)
(Figure 1). The PMN is microenvironment changes that occur in the secondary organ before
circulating tumor cells (CTCs) arrive to form the metastatic niche. Early PMN changes like
vascular leakiness and recruitment of special cells are caused by secreted factors and
extracellular vesicles from tumor cells (2). The second step is invasion and enhanced
motility of the tumor cells. Invasion involves changes to the extracellular matrix (ECM),
allowing cells to move through tight, and constricting spaces. Many changes occur to cell
morphology and internal signaling, allowing cells to use different types of migration and
detach or adhere from other cells and matrices (1, 3). The invasion step is directly involved
with intravasation, as it is the process of cells entering into a vascular or lymphatic
compartment. At this point, cells need to develop plasticity to adapt to the different
environments and forces they will be exposed to in a vascular compartment. It is known
that some cells require the genetic switch to a mesenchymal phenotype, using the epithelial
to mesenchymal transition (EMT). Still, once entering the vascular compartment, they may
switch back to epithelial (4). The EMT process may not be required for all cancer cells to
metastasize, but cells usually display plasticity as they are going through this process (1,
4). Cells also must be able to enhance survival mechanisms during this stressful process
1

to circulate through the vasculature and ultimately extravasate into the new tissue/organ
environment. Extravasation requires activation of multiple cytoskeleton processes to aid in
adhesion of the tumor cell to the endothelial cells, disruption of the endothelial layer, and
migration (5). Platelets, neutrophils, and macrophages also help promote tumor cell
extravasation by releasing certain factors (MMPs, TGFb, VEGF) that mediate the
interaction between tumor and endothelial cells (5). The final step of the metastatic cascade
is colonization and growth. This new environment, called premetastatic niche (PMN), must
support the tumor cell survival even before its arrival. The tumor cells may need immune
cells and/or secreted factors in the environment to allow for colonization and growth (1);
without such factors, tumor cells are subjected to a long-term dormancy period. There are
specific patterns of metastasis across different cancer types; this is supported by Dr.
Paget's "seed and soil" hypothesis (6). This hypothesis states that tumor cells that are
successfully metastatic, the "seed," interact with the microenvironment, the "soil". The
crosstalk of the cell and microenvironment will influence the metastatic site (7).
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Figure 1. The Metastatic Cascade. A process is consisting of invasion, intravasation,
extravasation, and colonization. There are immune cells and stromal cells in the tumor,
which help to inhibit immune response and facilitate angiogenesis and stromagenesis.
Tumor cells will invade and migrate to leave the primary tumor and intravasate into the
blood vessel. Interaction with other immune/blood cells in the vessel allows for survival of
disseminating tumor cells in suspension under sheer pressure; the tumor cell will leave by
extravasation and form colonies at distant organs- brain, bone, liver, or lungs. The figure
was created with BioRender.com.

Breast Cancer Metastasis
Breast cancer (BC) is classified into different subtypes based on molecular and
histological characteristics, essential for determining therapy treatments. Tumors are
grouped based on the expression of estrogen receptor (ER), progesterone receptor (PR),
and/or human epidermal growth factor receptor (HER2), and also the lack of
3

overexpression of those receptors, which is triple-negative breast cancer (TNBC). The
clinic uses five classification groups currently: Luminal A (ER+,PR+,HER2-), Luminal BHER2- (low ER+, PR+, HER2-), Luminal B-HER2+ (low ER+, PR+, HER2+), HER2enriched (ER-, PR-, HER2+), and Triple Negative (ER-, PR-, HER2-) (8). The HER2enriched and Triple Negative subtypes are most aggressive with increased proliferation,
higher grade, and genetic stability. Tumors that overexpress ER, PR, or HER2 generally
respond well to receptor-targeted therapies, have an intermediate to good prognosis, and
a 5-year survival rate above 80% for regional disease. TNBC tends to have a poor
prognosis due to the aggressive phenotype, lack of targeted therapies, and a 5-year
survival rate of 65% for regional disease (SEER data).
Metastatic breast cancer is an incurable disease that is the ultimate cause of death
in BC patients. The 5-year survival rate for patients with distant metastases significantly
decreases to 30-40% for Luminal or HER2 expressing tumors and 11% for TNBC (SEER
data). The most common metastatic sites for breast cancer include bone (67%), lymph
nodes (30-50%), liver (40%), lungs (36%), brain (12%), peritoneal cavity (10%), and
contralateral breast (6%) (8). It is interesting to note that the different subtypes of BC have
different patterns of metastasis; due to their genetic alterations, not all subtypes have the
same percentage of metastasizing to the bone (8). Metastatic disease recurrence occurs
at different time points with Luminal or HER2 tumor occurrence at 5-10 years; however,
TNBC occurrence is within two years (8).
Metastasis research is ultimately asking the question of what causes a tumor cell to
metastasize. Even though extensive research is being done, there is still no exact answer
to this question. The metastatic process is very complex, as described above. The
4

molecular tumor classifications bring additional complexity to the process. Identifying
factors that could determine if a tumor cell will metastasize and what makes them
metastatic is the goal of this field.
Aurora Kinase A in Cancer
Aurora Kinase A (AURKA) is a mitotic kinase among family members Aurora B and
Aurora C. Its canonical functions include: regulation of centrosome maturation and
separation, mitotic entry, bipolar spindle assembly, chromosome alignment, and
cytokinesis (9). Under non-pathological conditions, AURKA localization is only documented
at the centrosomes. In mitosis, AURKA can also be detected on the microtubules of mitotic
spindles. AURKA protein and its activity gradually increase as the cell progresses from the
S phase to G2 to Mitosis in the cell cycle. Still, the decrease and inactivation of AURKA is
required for mitotic exit (9). The autophosphorylation of T288 residue is necessary for
AURKA activation. This autophosphorylation is activated by binding partners (TPX2,
NEDD9, Ajuba, and PAK1) via a conformational change in AURKA (10). AURKA
inactivation is done by protein phosphatase 1 (PP1). The PP1 dephosphorylates AURKA
enabling ubiquitination by anaphase-promoting complex/cyclosome (APC/C) and
proteasomal degradation (10).
AURKA was identified as an oncogene in 1998 after two studies showed AURKA
amplification, overexpression, and transformation activity in colorectal cancers and breast
cancer cell lines (11, 12). Amplification of AURKA DNA on chromosome 20q13 has been
documented in multiple cancer types, including breast (13), bladder (14), and ovarian (15)
tumors. There is also evidence of increased protein expression and mRNA expression in
tumors and cell types (12, 16). High AURKA expression positively correlates with
5

proliferation marker, Ki67, poor overall survival, and recurrence of TNBC patients (17). It
was also shown to correlate with increased pathological states and predicts poorer
prognosis in lung cancer (18) and glioblastoma (19). The amplification and overexpression
of AURKA leads to chromosomal instability, aneuploidy and transformation of normal cells
(12, 20). The oncogenic AURKA is not restricted to localize at the centrosomes but has a
diffuse cytoplasmic localization (16, 21). There is also more recent evidence showing
AURKA localization in the nucleus (22-24).
Regulators of AURKA
Many positive and negative regulators of AURKA contribute to transcriptional,
translational, protein stability, and kinase activity regulation (25). Because overexpression
and amplification of AURKA is needed for its oncogenic role, the regulators summarized
below are positive regulators of AURKA. Regulators that promote AURKA transcription
include ARID3A (26), PUF60 (27), E4TF1 (28), TRAP220/MED1 (29), EGFR/STAT5 (30),
β-catenin/TCF4 (31), Myc (32), and FOXM1 (33). These transcriptional regulators bind to
the designated regions in the AURKA promoter and increase AURKA transcription
(mRNA). The translation of AURKA was shown to be upregulated by hnRNP Q1 through
binding to AURKA's 5’-UTRs (34). Multiple proteins protect AURKA from degradation,
increasing its stability, including NEDD9 (35), TPX2 (36), PUM2 (37), LIMK2 (38), Twist
(39), ALDH1A1 (40), YBX1 (41), and USP2a (42). The kinase activity of AURKA is
regulated through autophosphorylation of Thr-288 (9). Several proteins assist AURKA in
this process, including NEDD9 (35), TPX2 (43), PUM2 (37), PKC (44), PAK1 (45), Ajuba
(46), KCTD12 (47), and RASSF1A (48). There are 432 unique AURKA interactors
currently documented in the literature (BioGrid). The list is growing, supporting the
6

fundamental role this protein plays in cellular physiology under normal and pathological
conditions. Regulators of AURKA are summarized in Figure 2.

Figure 2. Positive regulators of AURKA regulate transcription, protein stability, and
kinase activity. Figure adapted from Du et al. (25). Figure was created with
BioRender.com.
Inhibition of AURKA kinase activity
Several small-molecule compounds have been discovered to inhibit the kinase
activity of AURKA (25). Some are specific to AURKA, but others have pan-specific effects
on the Aurora kinase family (AURKA/AURKB/AURKC). These molecules are termed
Aurora Kinase Inhibitors or AKIs. One of the most extensively studied AKIs with strong
7

specificity to AURKA is MLN8237 (Alisertib) (49). MLN8237 was shown to be 200-fold more
selective to AURKA than AURKB kinase and very effective at reducing tumor growth in
multiple xenograft models (49). MLN8237 is currently in multiple clinical trials for various
cancer types (clinicaltrials.gov), and the majority of these studies are in combination with
other drugs. The AKIs enhance the efficiency of other drugs when used in combination (5053). Due to the importance of AURKA in mitosis, the AKIs in the clinic cause significant
adverse side effects in patients. Among reported adverse effects, the most common were
fatigue, nausea, and neutropenia (54). Hence, there is ongoing research to use
nanoparticle technology to encapsulate AKIs for targeted tumor delivery to decrease
adverse side effects (55).
Non-Canonical Cytoplasmic AURKA
The cytoplasmic (non-centrosomal) localization of oncogenic AURKA allows
interaction with and phosphorylation of numerous cytoplasmic proteins, leading to its noncanonical cytoplasmic functions: migration and invasion, stem-like phenotype, EMT,
proliferation, and survival (25). Note that these studies did not consider the presence of
nuclear AURKA. Thus, it is possible that observed phenotypes at least partly were driven
by the nuclear and not cytoplasmic pool of AURKA.
Invasion/Migration: AURKA was shown to enhance migration and invasion through
phosphorylation of key cytoskeleton substrates. In immortalized fibroblasts, AURKA
expression was shown to increase migration by phosphorylation of FAK, PLD2, and
interaction with Src leading to increased tubulin polymerization (56). In head and neck
cancer, AURKA increased migration and invasion through phosphorylation of Akt and FAK
(57). Other mechanisms of AURKA-driven increase in migration and invasion involve
8

phosphorylation/activation of cortactin (58), Akt1 (59), Src (60), and the cofilin-F-actin
pathway (61). Phosphorylation of targets is summarized in Figure 3.

Figure 3. AURKA interactors leading to increased invasion and migration. They are
either dependent on AURKA phosphorylation or protein interaction to become activated.
This Figure was created with BioRender.com.
EMT: The epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial
(MET) are important processes that allow cells to have the plasticity to switch from epithelial
to mesenchymal molecular pathways (62). This is important in metastasis to enable cells
to leave the primary tumor, enter the vasculature, survive, and exit to other distant organs.
Those steps require different molecular pathways to be active/repressed to be successful
(62). AURKA was shown to phosphorylate Twist at three different residues, further
9

increasing the expression of other EMT markers: CD44, Slug, and Snail (39). Alternatively,
AURKA can induce EMT through MAPK phosphorylation leading to the upregulation of
EMT signature genes in multiple models (63, 64). Inhibition of AURKA was shown to
reduce expression of key transcription factors regulating EMT such as Twist, Snail/Slug
and markers of EMT such as N-cadherin and increase E-cadherin, suggesting a transition
from EMT to MET. This group also showed that AURKA inhibition led to decreased Akt and
GSK-3β phosphorylation (decreased PI3K/Akt and Wnt/β-catenin pathways) and led to
increased histone methylation at the Twist promoter (65). Induction of EMT also leads to
increased invasion and metastasis, indicating that AURKA can regulate these processes
directly via phosphorylation of FA, Src, Cofillin, tubulin etc., or indirectly via activation of
EMT transcription factors.
Stemness: The expression of AURKA positively correlates with cancer recurrence
(17), which is often driven by the presence of cancer stem cells (CSCs) (66). In ovarian
CSCs, therapy resistance and recurrence were shown to be dependent on AURKA-driven
NFκB signaling. The inhibition of AURKA led to cell death and an increase in nuclear IκBα,
which sequesters NFκB inhibiting its activity (67). In glioma initiating cells (GICs), AURKA
regulates their self-renewal by phosphorylation/stabilization of β-catenin, leading to Wnt
pathway activation (68). In breast cancer cells, overexpression of AURKA led to an increase
in CD44+/CD24- cell population and increased mammosphere formation (33). Similarly,
with the depletion of AURKA, there was a decrease in CD44+/CD24- population and
mammospheres (33). In colorectal CSCs, AURKA is overexpressed and regulates the
tumorigenic ability of these cells due to genomic instability (69). Silencing AURKA
expression led to growth inhibition and sensitivity to chemotherapeutic agents (69),
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indicating the significant therapeutic potential of AURKA targeting in combination with
chemotherapy.
AURKA is also known to interact with oncogene Myc – a transcription factor that
contributes to many oncogenic processes, including stemness (70). AURKA-dependent
phosphorylation was shown to stabilize N-Myc via inhibition of its degradation (71, 72),
resulting in the continued proliferation of Myc-addicted cancer cells. The protein and
transcript expression of AURKA and Myc has been shown to correlate in certain cancers
(71), indicative of a positive feedback loop and regulation on the transcriptional level (32,
73). Due to the feedback loop and stability of the AURKA-Myc complex, the two oncogenes
seem to enhance tumorigenesis, which led to studies investigating the inhibition of this
complex (74). Cancer stem cells have self-renewal, tumor-initiating, and colonizing
capabilities due to their stem cell-like gene signatures, including genes involved with EMT.
AURKA's vast regulation in stemness, EMT, migration, and invasion show the importance
of AURKA in the metastatic cascade.
Non-canonical Nuclear AURKA
More recently, AURKA localization in the nucleus was reported in biopsies across
multiple types of cancer, including oral squamous cell carcinoma (24), esophageal
squamous cell carcinoma (22), ovarian carcinoma (75), and lung cancer (23). It is important
to note that in these samples, along with nuclear AURKA, there is also a diffuse cytoplasmic
AURKA staining. In ovarian cancer, it was shown that overexpression of nuclear AURKA
led to worse overall survival and correlated with higher stage, higher grade, and larger
tumor size (75). There have been only a few studies evaluating the role of nuclear AURKA,
and those point towards nuclear AURKA being more oncogenic than cytoplasmic AURKA
11

(76). The authors used a functional Ras-induced transformation assay to determine the
oncogenic potential of WT-AURKA (nuclear and cytoplasmic) or NES-AURKA (nuclear
exclusion signal, cytoplasmic). The results suggested that only cells with nuclear AURKA
but not cytoplasmic AURKA possess the cell transformation activity and cooperate with Ras
(76). Following this initial observation, a few more studies had been conducted using
AURKA overexpression models and documented the function of nuclear AURKA
promotion/activation of transcription (33, 73, 77). Recalling the Myc-AURKA relationship,
Myc was shown to transcriptionally upregulate AURKA (32), while AURKA was shown to
transcriptionally upregulate Myc (73). In a model of hepatocellular carcinoma (HCC) in
which cells have nuclear AURKA, depletion of AURKA led to decreases in Myc mRNA and
protein levels. Chromatin immunoprecipitation (ChIP) assays further revealed that AURKA
binds to Myc promoter regions (73), suggesting for the first time that AURKA possesses
transcriptional functions and transcriptional domains. These results were confirmed in
breast cancer cells discovering the hnRNPk protein as the necessary DNA-binding partner
of AURKA at the Myc promoter (77). In a similar model of BC, AURKA transactivates
transcription factor FOXM1 (33), which in turn positively re-enforces AURKA transcription,
creating yet another positive feedback loop. AURKA and FOXM1 were shown to co-localize
in the nucleus by immunofluorescence and interact with each other by coimmunoprecipitation (33).
These recent studies have shown that nuclear AURKA regulates and augments
breast cancer stemness (33, 77). The study done by Zheng et al. (77) establishes the
importance of nuclear AURKA expression in supporting the stem cell population. The
depletion of AURKA resulted in a decreased population of stem cells (CD24low/CD44high
12

cells). When utilizing the model of inducible AURKA in the cytoplasm by an NES tag or WTAURKA found in both compartments, researchers found that cells with only cytoplasmic
AURKA had lost stem-like properties as manifested by the decrease in mammosphere size
and number are decreased. Having AURKA in both nuclear and cytoplasmic compartments
is needed to increase the stem cell population and mammosphere forming ability,
suggesting that the nuclear pool of AURKA enhanced stem cell function (77).
Gaps in Nuclear AURKA Research
A significant gap in nuclear AURKA research is the mechanisms of nuclear
translocation of AURKA are currently unknown. It was shown that amino acids 333-383 of
AURKA in the catalytic domain (amino acids 133-383) (78) are required for nuclear
targeting (77). Although no NLS has been identified, suggesting that the nuclear localization
is due to protein-protein interaction/s within this region. The authors also claim that amino
acids 1-333 are responsible for cytoplasmic localization/retention (77). More research is
needed to fill this gap in the nuclear AURKA field.
Hypoxia
Hypoxia is a state of low oxygen, around 1-2% O2 and below, compared to its normal
oxygen level, termed normoxia (79). The normal oxygen levels of different tissues vary; for
example, the breast has a median oxygen level of ~7%, but the brain is ~4% (80, 81).
However, the tumor counterpart is much lower, with breast cancer ~1.3% O2 and brain
cancer ~1.7% O2 (80, 81). In the literature, it is widely accepted that 20% O2 is considered
normoxia levels for in vitro studies, even though normoxia levels in tissues are well below
this (82). Hypoxia is one of the hallmarks of cancer and is associated with disease
progression and dissemination (82, 83).
13

Hypoxia Transcriptional Regulation
As cells in the tumor become deprived of oxygen, they activate the hypoxia response
signaling cascade to alleviate/compensate for this deficit. The induction of the hypoxia
signaling cascade depends on hypoxia-inducible factors (HIFs), a family of transcription
regulators. This family consists of alpha subunits (HIF1α, HIF2α, HIF3α) in which protein
stability and degradation are dependent on oxygen sensors, prolyl hydroxylases (PHDs),
and factor inhibiting HIF1 (FIH1) (84). The beta subunits (HIF1β and HIF2β) are oxygenindependent but required for heterodimerization and transactivation (85). In normoxia, HIFα subunits are hydroxylated by PHDs and FIH1 (84). The hydroxylated HIFs are then
ubiquitinated by the E3 ubiquitin ligase, von-Hippel Lindau (VHL), and degraded by the
proteasome (86). Due to HIF-α subunits being constantly degraded, the HIF-β subunits
cannot heterodimerize, ultimately leading to a lack of gene transcription. In the hypoxia
settings, the PHDs and FIH1 enzymes become inactive due to the low oxygen needed for
their function and thus unable to hydroxylate the HIF-α subunits (84). The HIF-α protein
accumulation results in heterodimerization of HIFα/β subunits and translocation into the
nucleus (85, 87). In the nucleus, HIFα/β dimer binds to hypoxia response elements (HREs)
on DNA/promoter regions in cooperation with other cofactors CBP/P300, initiating
transcription of hypoxia target genes (88) (Figure 4).
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Figure 4. Normoxia and Hypoxia signaling in cells. In normoxia, PHD's hydroxylate
HIF1A, which is then recognized by VHL to promote ubiquitination and degradation. HIF1B
is not able to bind with HIF1A, resulting in no transcriptional complex. In hypoxia, PHDs
become inactive, meaning HIF1A is not hydroxylated, thus increasing protein levels. HIF1A
is able to bind HIF1B and translocate into the nucleus. HIF1B has NLS targeting it to the
nucleus. The heterodimer binds to HRE regions and forms a complex with other cofactors
CBP/P300, and transcription of HIF target genes is activated. The Figure was created with
BioRender.com.
Hypoxia in Breast Cancer
The HIF1α expression levels in cells and tissues are the most common read-out for
hypoxia and activation of hypoxia signaling. It has been shown in multiple cancer types,
including breast cancer, in which HIF1α expression correlates with cancer progression (89).
It was also demonstrated that overexpression of HIF1α leads to poorer patient survival (89,
15

90). Interestingly, patients with elevated HIF1α levels show a faster onset of metastasis
and metastases outgrowth. The HIF1α overexpression was detected in BC metastases
more often than the primary tumor (89, 91), suggesting a strong involvement of HIFs in
tumor progression and metastasis.
HIF Target Genes
Hypoxia is an important mechanism for cancer progression and metastasis, as it
induces genes involved in angiogenesis, metabolism, invasion, transcriptional regulators,
EMT, stemness, and more (92-94) (Figure 5). These genes, when activated, promote tumor
cells to adapt to harsh (low oxygen/nutrients) conditions within the tumor microenvironment.
Angiogenesis is an essential part of metastasis as it provides routes for tumor cells to
escape and disseminate to other organs (95) and supply oxygen. Essential genes involved
in angiogenesis and are regulated by HIF signaling include VEGF (96), angiopoietin1/2,
Tie2 (97), and PDGF (98). HIF-induced genes that are involved with increasing invasion
and stemness include adhesion molecules like ITGA6 (99), matrix-degrading enzymes like
MMPs (100), cytokines like CXCR4 (101, 102), and ADM (103). These genes were shown
to be induced by HIFs and contribute to inducing the metastatic cascade.
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Figure 5.HIF targeted genes. Hypoxia-inducible factor (HIF) targets various genes
affecting tumor progression and metastasis. Figure adapted from Dengler et al. (93),
Semenza (104), Tsai and Wu (92) and created with BioRender.com.
AURKA and Hypoxia
There have been few studies showing a relationship between AURKA and
hypoxia/HIF1α. The AURKA and HIF1α coexpression better correlate with worse overall
survival than the single expression counterpart (105, 106). In neuroblastoma and
hepatocellular carcinoma patients, induction of hypoxia was shown to increase AURKA
protein and mRNA expression (106-108). However, opposite results were reported in one
model of breast cancer where induction of hypoxia was shown to decrease AURKA mRNA
expression and AURKA promoter activity. Knockdown of HIF1α leads to increased AURKA
17

mRNA expression (109). These results suggest that regulation of AURKA by hypoxia may
differ between cancer models/types. The role of nuclear AURKA in hypoxia/HIF signaling
is currently unknown.
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Abstract
Metastatic breast cancer causes most breast cancer-associated deaths, especially in
triple negative breast cancers (TNBC). The metastatic drivers of TNBCs are still poorly
understood, and effective treatment non-existent. Here we reveal that the presence of
Aurora-A Kinase (AURKA) in the nucleus and metastatic dissemination are molecularly
connected through HIF1 (Hypoxia-Inducible Factor-1) signaling. Nuclear AURKA
activates

transcription

of

“hypoxia-induced

genes” under normoxic

conditions

(pseudohypoxia) and without upregulation of oxygen-sensitive HIF1A subunit. We
uncover that AURKA preferentially binds to HIF1B and co-localizes with the HIF complex
on DNA. The mass spectrometry analysis of the AURKA complex further confirmed the
presence of CBP and p300 along with other TFIIB/RNApol II components. Importantly,
the expression of multiple HIF-dependent genes induced by nuclear AURKA (N-AURKA),
including migration/invasion, survival/death, and stemness, promote early cancer
dissemination. These results indicate that nuclear, but not cytoplasmic, AURKA is a novel
driver of early metastasis. Analysis of clinical tumor specimens revealed a correlation
between N-AURKA presence and decreased patient survival. Our results establish a
mechanistic link between two critical pathways in cancer metastasis, identifying nuclear
AURKA as a crucial upstream regulator of the HIF1 transcription complex and a target for
anti-metastatic therapy.
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Introduction
AURKA is a serine/threonine kinase responsible for centrosome maturation,
separation, and spindle formation during mitosis (1). Normal localization of AURKA is at
the centrosomes/cytoplasm (2). AURKA is also involved in the regulation of migration
and invasion (3).
AURKA has recently been reported to localize in the nucleus in various cancers,
such as colon (4), lung (5), and breast (6). Few reports demonstrate the oncogenic
potential of nuclear (N-AURKA), but not cytoplasmic, AURKA in cooperation with Ras
(7) and Myc (6) oncogenes. AURKA phosphorylates multiple nuclear proteins that
promote carcinogenesis, including p53 (8), Akt (9), and NFkB (10), suggesting that
these might be targets of nuclear AURKA.
High expression of AURKA was shown to correlate with earlier recurrence of
TNBC in patients (11) and indicative of disease progression. The increased AURKA
expression was established to promote metastasis by enhancing epithelial to
mesenchymal transition (12), stemness (6), and invasion (3). Although expression of
AURKA in the nucleus correlates with poor overall survival (13), the mechanism driving
cancer progression associated with N-AURKA is currently unknown.
Hypoxia is a physical state of lower oxygen compared to normal oxygen levels
(normoxia). When a cell experiences hypoxia, the hypoxia-inducible factors (HIFs)
consisting of alpha/beta subunits (HIF1/2A, HIF1/2B) are stabilized. The HIFA/B
heterodimer then translocates into the nucleus, where it binds to DNA on hypoxiaresponsive elements (HREs) (14), regulating transcription of genes involved in
proliferation, apoptosis, angiogenesis, and metabolism (15). The association between
HIF1 expression, hypoxia genes/signaling, and metastatic breast cancer has been
previously documented (15-17).
Here we report, that N-AURKA via binding to HIF complexes activates hypoxia
transcriptional programs independent of HIF1/2A stabilization in cells exposed to
atmospheric oxygen (18). Transactivation of hypoxia genes leads to increased
migration/invasion and stemness, enabling dissemination and metastases at distant
organs without significant delay or dormancy. Inhibiting N-AURKA kinase activity with
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Alisertib/MLN8237, AURKA specific inhibitor, significantly reduces metastatic
colonization but does not block dissemination. Hence, using nuclear AURKA-targeting
compounds in combination with HIF inhibitors might prove beneficial in treating
metastases in TNBCs and other cancers. The presence of cells with N-AURKA could
serve as a surrogate for metastatic cells and indicate early dissemination.
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Materials and Methods
Cell Culture, plasmids, and reagents. Cell lines MDA-MB-231, BT-549, HCC1143,
Hs578t, MCF7, MCF10A, SK-BR-3, and BT-474 were purchased from and authenticated
by American Type Culture Collection. MDA-MB-231LN (PerkinElmer) were grown based
on manufacturer’s recommendations, low passage cells were used in the study. The
sgRNAs, siRNAs, primers for site-directed mutagenesis is outlined in Suppl.Table S1.
Details about lentivirus constructs/production/infection and reagents are outlined in
Supplementary Methods.
Western blotting (WB). Cells/tumors were either lysed in Laemmli or M-PER lysis buffer
(ThermoFisher) and processed as previously described(19). Proteins are normalized to
loading controls (GAPDH or tubulin), n=2 biological/clones, n=2-3 experiments.
Antibodies and dilutions are listed in Suppl.Table S2.
Immunofluorescent cell analysis. Immunofluorescence was performed as previously
described (20). Images were captured using a Zeiss/LSM-510 confocal microscope with
63X Plan-Apochromat/NA1.4, oil objective. 3D-confocal images were processed using
Zen and ImageJ/NIH software. Images inside each data set were collected with the same
microscopy/image capture settings. Antibodies used are listed in Suppl.Table S2.
Immunohistochemistry (IHC). The detailed protocol for processing and analysis of
Fluorescent-IHC and DAB-IHC is outlined in the Supplementary Methods.
Tissue Microarray and Patient Data. Breast cancer survival data were evaluated using
the breast cancer gene chip data of the online databases Kaplan-Meier Plotter (21, 22),
the best cutoff values were selected according to the defined high or low expression of
AURKA, HIF1A/B, N-AURKA-signature genes. High-density breast cancer TMA BR2082
(US Biomax Suppl.Tables S3 and S4) were collected with full donor consent under the
approved IRB protocol. The detailed protocol is outlined in the Supplementary Methods.
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Nuclear/Cytoplasmic Fractionation. The detailed protocol is outlined in the
Supplementary Methods.
Cell viability analysis. Guava/Viacount (Luminex) reagent and Guava Eascyte-HT Flow
Cytometer (Millipore) were used for analysis of cell viability per manufacturer’s
instructions. 1x105 cells/well in a 12-well plate were collected 24-120hr post-plating.
Parameters for the flow cytometer were set using positive (live) and negative (dead)
cells/controls. n=2 experiments with n=2 biological, n=2 technical replicates.
Cell elongation and nuclear size analysis. 1x104 attached cells/well were stained with
Hoechst33342 (ThermoFisher) and bright field images captured using Zeiss-Axio ImagerZ2 microscope, 20x Plan-Apochromat/0.80NA objective. Cell elongation was measured
as a function of cell length divided by cell width in ImageJ software. 50 cells/condition
quantified in 3-4 random fields with n=2 biological/clones, n=2 technical replicates.
Live-cell imaging of individual cell invasion/migration. Protocol and quantification
methods were previously reported (23). 2.5x105 cells were imaged with confocal
microscopy, 2µm/steps. n=3 experiments with n=2 biological, n=2 technical replicates,
and ≥50cells traced/per condition.
Anoikis assay. The detailed protocol is outlined in Supplementary Methods.
Flow cytometry analysis. The staining, collection and gating protocols outlined in
Supplementary Methods. Antibodies used are listed in Suppl.Table S2.
Mammosphere Assay. Mammosphere assay was done as described (6). At day 10,
mammospheres were imaged on ECHO Rebel microscope (VWR) at 4X and 10X.
Analysis of sphere’s diameter and number was done in ImageJ. n=2 experiments, n=2
biological/clones, n=3 technical replicates per group with 100 cells counted in 6-10
random field/condition.
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Orthotopic xenograft models of breast cancer. Orthotopic injections, bioluminescent
imaging, and ultrasound of xenografts were performed as described (24). All procedures
were approved by the WVU Institutional Animal Care and Use Committee and followed
guidelines established by the NIH. Details for the orthotopic experiments are outlined in
the Supplementary Methods.
RNA Sequencing and Bioinformatics. Total RNA was isolated from cells (2
clones/construct) with RNeasy Mini-kit (Qiagen). The RNA sequencing data were
generated by the WVU Genomics core facility and deposited to GEO with accession
number GSE154494. The detailed protocol is outlined in the Supplementary Methods.
Quantitative RT-PCR. RNA (RNeasy Mini-Kit) was used for cDNA generation with
MaximaH-Minus First-Strand cDNA-Synthesis kit (ThermoFisher). Custom Taqman-Array
in 96-well format (AppliedBiosciences #4391524) was created based on RNA
sequencing. The detailed protocol is outlined in the Supplementary Methods. Primer
assays and sequences are listed in Suppl.Table S5.
Mass Spectrometry. The 6x106 cells (MDA-MB-231-NES/or NLS-AURKA) were used (2
clones combined/cell line). The detailed protocol is outlined in Supplementary Methods.
Immunoprecipitation (IP) assay. The detailed protocol for immunoprecipitation of
AURKA is outlined in Supplementary Methods.
Chromatin Immunoprecipitation Assay. Chromatin immunoprecipitation (ChIP) was
performed using ChIP-grade antibodies against human AURKA (BethylLabs, #IHC00062) and the SimpleChIP Enzymatic ChromatinIP Kit (CellSignaling) according to
manufacturer’s instructions. The detailed protocol is outlined in Supplementary Methods.
The primers used for ChIP qPCR analysis are listed in Suppl.Table S6.
Statistical analysis. Statistical comparisons were made using two-tailed Student’s t-test,
one-way or two-way analysis of variance (ANOVA). P≤0.05 was considered to be
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significant (*). All groups were compared to empty-vector control/s unless mentioned
otherwise. Experimental values were reported as the means with +/-S.E.M (standard error
of mean), p-values are reported as adjusted, and calculations of statistical signiﬁcance
were made using Prism7 software (Graphpad Software). All experimental data sets
reported here were collected from multiple independent experiments with multiple
technical and biological replicas. The analyses were performed by staff on numbered, deidentified samples.
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Results
Nuclear localization of AURKA correlates with disease progression and metastasis.
AURKA overexpression in TCGA BC cohort correlates with poorer overall survival
(Suppl.Fig.1A-C), but this dataset does not allow stratifying patients based on subcellular
localization of AURKA. To fill this gap, a BC tissue microarray with over 200 patient
samples (Suppl.Table-S3) was analyzed for AURKA localization and correlated with
pathological stage and subtype (Fig.1A-C). The positivity of normal tissue and ductal
carcinoma in-situ (DCIS) for N-AURKA is 0-3%. There is a ten-fold increase in positivity
in invasive ductal (IDC), lobular (ILC) carcinomas, and metastases (MIDC-LN) (Fig.1AB). The TNBC and HER2+ tumors show up to 12-20% of cells in the tumors with NAURKA compared to 5% of ER/PR+ cases (Fig.1C). To evaluate the association between
N-AURKA positivity in clinical samples and metastasis, we have procured a set of
matched breast tumor-metastases biopsies along with biopsies from patients who had no
metastases at the time of biopsy (IRB#WVU011113, Suppl.Fig.1D, Suppl.Table-S4).
Spearman’s rank correlation coefficient analysis indicated a strong correlation between
N-AURKA positivity and metastatic outcomes (Suppl.Fig.1E, r = 0.8051, p<0.0001).
Eleven of these biopsies were previously used to produce patient-derived xenograft
(PDX) models (25). Similar to the original biopsy, the low/negative N-AURKA PDXs
(PEN_060, PEN_061, PEN_175, PEN_181, PEN_025) had no distant metastases, while
N-AURKA high (PEN_014, PEN_056, PEN_76, PEN_116) developed metastases
(Suppl.Table-S4), indicating that N-AURKA correlates with metastasis. The AURKA
localization/expression in BC cell lines shows a correlation between nuclear AURKA
positivity and metastatic potential of the cells (Fig.1D-E, Suppl.Fig.1F-G).
N-AURKA drives cancer migration/invasion but does not affect proliferation.
To define the impact of N-AURKA on metastasis, cells with nuclear or cytoplasmic
AURKA were produced. The cell lines (MDA-MB-231 and BT549) were made using
CRISPR/Cas9 to knockout endogenous AURKA and replace with exogenous AURKA
targeted to the nucleus (NLS), cytoplasm (NES), or no-localization signal (WT) (Fig.1FH, Suppl.Methods). The cells expressing non-targeting sgRNAs and empty vectors were
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used as controls. In vitro cell proliferation/viability assay and mixed modeling analysis
show no statistically significant differences in cell growth or death between NLS- and
NES-AURKA cells (Fig.2A). The morphometric analysis of NLS-AURKA cells shows
reduced cell elongation index and nuclei (Fig.2B-D). The 3D invasion assay in collagen
shows that NLS-AURKA cells travel a significantly longer distance and are faster than
other cells (Fig.2E-H). In agreement with previously published reports, the MDA-MB-231
cell viability was not compromised due to attachment loss (Fig.2I). Interestingly, all cells
expressing exogenous AURKA were more resistant to anoikis, but no differences were
observed between sublines. The analysis of the number and size of multi-cellular clusters
at 48h post-seeding shows a significant decrease in the clumping/clustering potential of
NLS-AURKA cells without effecting cell viability (Fig.2J-K), suggesting that clumping may
not be necessary for the survival of these cells. These results indicate that cells with NAURKA are highly invasive but do not possess enhanced proliferation or anchorageindependent capabilities.
N-AURKA drives cancer cell stemness.
The cell-surface antigens, CD24, CD44, and CD104, are used as cancer stem cell
(CSC) markers (26, 27). Similar to previous reports, there is a decrease in the
CD24+/CD44+, CD24+/CD104+ cells and a significant increase in CD24-/CD44+, CD24/CD104- cells in NLS-AURKA cells, showing a shift to more stem-like (Fig.2L-O). A
decrease was observed in the number of stained cells for CD24 and the mean fluorescent
intensity (Suppl.Fig.2A), while CD44 mean fluorescent intensity was increased
(Suppl.Fig.2B-C). Previously, FOXM1 transcription factor was reported to mediate the
AURKA driven stemness (28). The analysis of stem cell markers shows no changes in
CD24, CD44, or CD104 upon depletion of FOXM1 (Suppl.Fig.2D-H), suggesting that this
activity of N-AURKA is FOXM1 independent. Similarly, analysis of mammosphere
formation shows a significant increase in the number and diameter in NLS-AURKA cells
(Fig.2P-R). Still, this activity was not affected by the depletion of FOXM1 (Supp.Fig.2I).
N-AURKA induces hypoxia in xenograft models of breast cancer.
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To evaluate the effect of N-AURKA on tumor invasion and metastasis in vivo, the
cells were injected into the mammary gland of immunocompromised mice (Fig.3A). There
were no significant differences in the growth of mammary tumors between groups
(Fig.3B, Suppl.Fig.3A-B). Even though tumors were of similar size/volume, there was a
significant

difference

in

tumor

necrosis

and

vascularization

(Fig.3C-G).

Immunohistochemistry analysis of the tumors showed no significant difference in
proliferation (Ki67) (Suppl.Fig.3C-E). The NLS-AURKA group showed a significant
decrease in CD31 staining compared to the control (Fig.3F-G). To assess oxygenation
of tumors, the hypoxia marker-pimonidazole was injected in mice before collection. Tumor
analysis shows that over 40% of NLS-AURKA tumors were hypoxic (Fig.3H-I).
N-AURKA expressing tumors are highly metastatic.
The induction of hypoxia often results in metastasis (29). The analysis of distant
organs shows over ten-fold increase in the number and size of metastases in mice
bearing NLS-AURKA tumors compared to other groups (Fig.4A-E, Suppl.Fig.4A-B). The
bone and liver metastases were present in all NLS-AURKA mice (100% penetrance rate)
(Fig.4C), suggesting that NLS-AURKA cells have an increased proficiency to
disseminate/grow at multiple distant sites.
N-AURKA induces hypoxia signaling via upregulation of HIF-responsive genes.
To identify the processes responsible for the increased metastatic potential, the
gene expression profiles of cells were generated (GSE154494). The presence of AURKA
in the nucleus was associated with a global transcriptional response (Fig.5A). Principal
component analysis of RNA-seq data separated the samples into three groups (Fig.5B)
with a significant number of genes differentially expressed in NLS-AURKA cells (Fig.5C,
Suppl.Fig.5A-B). The expression of some targets was evaluated by western blotting and
qPCR in MDA-MB-231 and BT-549 cells (Fig.5E-F, Suppl.Fig.5D-F). The N-AURKA
gene-signature was confirmed by qPCR in tumors showing a similar gene expression
profile (Suppl.Fig.5G-I). The Gene Ontology terms analyzed with the REViGO tool show
that NLS-AURKA upregulates genes related to differentiation, motility/adhesion,
hypoxia/oxygen, and protein phosphorylation (Fig.5D, Suppl.Fig.5C). Gene Set
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Enrichment Analysis (GSEA) showed enrichment for genes involved in mammary stem
cell development, EMT, and hypoxia (Fig.5G). The NLS-AURKA cells show upregulation
of genes associated with the hypoxia-response, such as CXCR4, MMP1, ANGPT1,
ARNT/HIF1Β, MMP14, ITGA6/CD49f, and ARNT2/HIF2B (Fig.5H). The IPA analysis of
RNA-seq identified multiple upstream regulators of hypoxia signaling, including HypoxiaInducible Factor-1 alpha (HIF1A), NFκB, and tumor necrosis factor (TNF) to be activated
in NLS-AURKA cells (Fig.5I). The N-AURKA-driven hypoxia gene signature correlates
with a worse prognosis and high risk of relapse (Suppl.Fig.5J-K), suggesting that hypoxia
genes identified in our study influence the disease progression.
N-AURKA binds to HIF1Α/Β and transactivates hypoxia response genes.
To understand how N-AURKA enables the transcription of hypoxia-response
genes, protein expression of Hypoxia-Inducible Factors (HIFs) was examined. DMOG
(dimethyloxalyl glycine) treatment was used as a positive control, leading to upregulation
and stabilization of HIF1/2A. In normoxia, there were no differences in protein levels of
HIF1/2A between the sublines (Fig.6A-B, Suppl.Fig.6A-B). The DMOG treatment led to
increased HIF1A protein independently of AURKA localization. In contrast, HIF2A was
not upregulated in DMOG-treated NLS-AURKA cells, suggesting differential action of
AURKA on these proteins during hypoxia, but not normoxia. Consistent with RNA-seq
results, a significant increase in HIF1/2B proteins was detected (Fig.6A-B, Suppl.Fig.6AE). To determine if N-AURKA interacts with HIFs, we immunoprecipitated AURKA from
cell lysates. The AURKA complex contained HIF1A and HIF1B proteins; NLS-AURKA
expressing cells preferentially precipitated AURKA in a complex with HIF1B (Fig.6C-D).
Next, the binding of AURKA to hypoxia-response gene promoters was assessed using
chromatin immunoprecipitation (ChIP) assay. The CD49f/ITGA6, EPO, and CXCR4
genes were selected as they contain Hypoxia Response Elements (HREs) (30-32). ChIP
for HIF1B was used as the positive control. The qPCR with FOXM1 promoter was used
as a positive control for AURKA (28). ChIP qPCR results show N-AURKA binding to HREcontaining promoters of specific hypoxia genes, also occupied by HIF1B (Fig.6E-F).
Other proteins that interact with N-AURKA on chromatin include hnRNPk, Aurora-B
Kinase, Histone H3 and Histone H2B (Fig.6F). To map the protein interaction network of
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N-AURKA, we carried out LC-MS/MS analysis of AURKA-IP complex. The identified
proteins were clustered based on the cellular compartment and biological function
(Fig.6G). A large subset of proteins was nuclear and classified as DNA/RNA-binding.
Notably, the two principal HIF transcription cofactors CBP and P300 were identified within
the AURKA complex, along with RNA PolII and multiple proteins involved with the super
elongation complex (Fig.6H-I).
HIF1A/B is required to mediate N-AURKA-driven invasion.
To test the role of HIF1A/B in mediating N-AURKA driven processes, we generated NLSAURKA and control cell lines with depletion of HIF1A/B (Fig.7A-B). The 3D
invasion/migration analysis shows a significant reduction in invasion of NLSAURKA/siHIF1 cells as documented by the decrease in speed and distance (Fig.7C-F).
The transactivation of hypoxia-signature genes was also significantly reduced upon
depletion of HIF1A/B (Fig.7G). Interestingly, depletion of HIF1A/B led to a decrease in
FOXM1 expression (Fig.7H). In comparison, depletion of FOXM1 did not change
expression levels of HIF1A/B (Fig.7I-J), suggesting that the N-AURKA/HIF complex is
upstream of FOXM1. Supporting this notion, mammosphere formation potential in NLSAURKA cells was not affected by FOXM1 depletion (Supp. Fig.2I).
Inhibition of N-AURKA kinase activity decreases breast cancer metastasis.
The orthotopic xenograft study was conducted using control and NLS-AURKA cells
treated with AURKA-specific inhibitor, Alisertib/MLN8237 (Fig.8A-B). The tumor volume
was not affected by Alisertib/MLN8237 treatment (Fig.8C), while metastases in the lungs
and liver were significantly decreased (Fig.8D-F), suggesting that kinase activity might
be required to enable metastatic colonization. The metastatic penetrance in the NLSAURKA group was not affected by the MLN8237 (Fig.8G) indicating that dissemination
of NLS-AURKA cells is kinase-independent. In summary, these findings support the
model of N-AURKA-driven activation of hypoxia-response genes via interaction with HIF1
promoting metastasis (Fig.8H).
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Discussion
AURKA has recently been found in the nucleus in multiple cancers (4-6, 33);
however, the role of nuclear AURKA (N-AURKA) in metastasis is currently unknown.
Here, we report that N-AURKA promotes metastasis. The AURKA subcellular distribution
in BC-TMA shows accumulation in the nucleus correlating with more aggressive
subtypes, invasive stage, and metastasis (Fig.1A-C, Suppl.Fig1E). The analysis of
TCGA data indicates a strong correlation between levels of AURKA mRNA and poor
outcomes (Suppl.Fig.1A-C). The NLS-AURKA induced hypoxia gene-signature
correlates with decreased overall and relapse-free survival (Suppl.Fig.5J-K). In human
breast cancer cell lines, the localization of AURKA in the nucleus closely correlates with
the metastatic proficiency of the cells (Fig.1D-E, Suppl.Fig.1F-G).
The critical role of N-AURKA in metastasis was documented by the enhanced
metastatic burden in orthotopic mouse models (Fig.4). The metastatic penetrance of
NLS-AURKA cells is 100% in the lungs, lymph node, liver, and bone (Fig.4C) without the
need for multiple rounds of selection (34, 35). NLS-AURKA upregulates genes that
promote bone metastasis, including ADAMST1, FGF5, FST, CXCR4, IL-11, MMP1 (34).
Note that tumor cells with cytoplasmic AURKA, found in non-transformed cells, have
limited to no metastatic capacity (Fig.2A, Fig.4).
The increased metastatic capabilities are supported by changes in morphology,
migration, and stemness. Cells with nuclear AURKA are round and small (Fig.2B-D),
enabling fast movement throughout a constricted environment (36, 37), as in the invasion
assay (Fig.2E-H). The upregulation of cytoskeleton (RHOJ, ARHGAP22, ARHGAP24,
ELMO1, DEF6), adhesion (CADM2, SELL, ITGA6), matrix-degrading (ADAMTS5,
ADAMTS1, MMP1, MMP14), and tight junction (CLDN4, CLDN11, CLDN12, CLDN23)
proteins enables metastatic proficiency of N-AURKA cells (Fig.5). The decrease in
extracellular matrix proteins (LAMB1, LAMC2) might explain the decline in cluster
formation (Fig.2J-K). Interestingly, clustering disability did not affect the sensitivity to
anoikis (Fig.2I) or metastatic proficiency (Fig.4), suggesting uncoupling of these
processes.
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The analysis of stem cell markers showed an increase in CD24-/CD44+ and CD24/CD104+ cells (Fig.2L-O) and a reduction in mean fluorescent intensity of CD24
(Suppl.Fig.2A-C). These findings agree with a recent study showing that N-AURKA
promotes breast cancer stemness (6). The NLS-AURKA cells produced more and larger
mammospheres, indicating an increase in stemness (Fig.2P-R). The depletion of FOXM1
was insufficient to change the stem cell markers or mammosphere formation
(Suppl.Fig.2D-I). This activity of N-AURKA might be mediated by HIF1A/B, which in turn
might upregulate FOXM1 (Fig.7H-J). These findings differ from previously published
reports, using either an overexpression system (28) or NES-AURKA inducible system (6).
Neither of those modeling approaches allows analysis of nuclear AURKA specific function
directly.
The RNAseq analysis show changes in expression of hypoxia, transcription, and
metastasis-related pathways (Fig.5, Suppl.Fig.5). It is well-established that hypoxia is an
inducer of metastasis (38, 39). Our findings show that NLS-AURKA interacts with HIF1
and is a potent inducer of the hypoxia-response genes in vitro and in vivo (Fig.6,
Suppl.Fig.6). Hypoxia signaling is primarily driven by hypoxia-inducible factors (HIFs).
The activation/expression of HIF1A at diagnosis is predictive of early relapse and
metastasis (40-43).
The NLS-AURKA-ChIP complex analysis and qPCR support the notion that AURKA is
binding to HRE-containing promoters with HIF1A/B (Fig.6E-I). These changes are
reported under normoxic conditions and could be further induced under hypoxia. A similar
phenotype was observed in other breast cancer models (44). N-AURKA gene-signature
changes were associated with metabolic reprogramming (HK1/2), angiogenesis (ADM,
ANGPT1, EDN1, FECH), invasion (CXCR4, LOX, MMP1, MMP14, ITGA6, CSRP2), and
proliferation (ENG, WT1, CCND1). Depletion of HIF1A/B in NLS-AURKA cells led to a
reduction in migration/invasion and expression of the key hypoxia signature genes,
suggesting that this metastasis-driving activity of AURKA is HIF1 dependent (Fig.7A-G).
Note that not all genes connected to hypoxia were upregulated. Some canonical HIF1Ainduced genes PFKP, SNAI1, and NOS3 were downregulated, suggesting the
involvement of additional factors affecting transcription (Fig.5I).
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The mass-spectrometry analysis of the AURKA-complex identified p300/CBP and
RNAPII complex proteins, supporting the role of N-AURKA in transcription (Fig.6G-I).
These findings are in agreement with the previous reports showing AURKA binding to the
MYC promoter (6). In concordance with this report, we show that nuclear AURKA binds
to chromatin complexes that contain hnRNPk (Fig.6F,H). The global ChIP-seq analysis
of AURKA has not been reported; therefore, many of the potential targets are still
unknown.
Previously it was shown that transcription-related activities of nuclear AURKA are kinaseindependent. In our study, inhibition of N-AURKA leads to a significant decrease in
metastatic burden (Fig.8). Interestingly, the kinase activity was not required for
dissemination but was critical for colonization of distant organs. Combining AURKA
inhibitors with HIF-targeting compounds might prove to be even more beneficial in treating
metastatic cancer (6, 25). A better understanding of the nuclear AURKA functions may
enable discovery of new biomarkers for metastatic disease and therapeutic targets.
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Figure Legends
Figure 1. Nuclear AURKA positivity correlates with metastasis and more
aggressive breast cancer subtypes. A. Representative images of tissue microarray
IHC, (n=206) stained with AURKA/DAB-brown, hematoxylin-nuclei/blue. Scale bar300µm. Insets-x250 enlarged areas. B-C. Quantification N-AURKA positive(+) cells as in
(A), 3 randomly-assigned fields, n=100 cells/field. (B) Pathological stages (Normal=32,
DCIS=24, IDC=72, MIDC-LN= 32, ILC=24) and (C) receptor-based subtypes (Normal=32,
TNBC=39,

HER2+=32,

ER+/PR+=30).

D.

WB

analysis

of

nuclear/cytoplasmic

fractionations, as indicated. E. Quantification of AURKA in cytoplasm/nucleus, percentof-total, normalized to controls. F. Schematic outline of cell line production. G-H.
Immunofluorescence and WB analysis of AURKA-sublines produced in (F) stained with
AURKA(green), RFP(red), DAPI-nuclei/blue; clones indicated as c1/c2/c3. Scale bar10µm. One-way ANOVA, +/-S.E.M, Dunnett’s test, ns=non-significant.
Figure 2. N-AURKA drives cancer migration/invasion but does not affect
proliferation. A. Cell proliferation/viability assay, mixed-effect model analysis on cell
growth. B. Representative bright-field images of cells, scale bar-10µm. C. Cell elongation
index and D. Nuclei size. E. Individual cell movement tracking-plots toward
chemoattractant. Graphs of F. Total distance, G. Cell-body directionality, H. Cell speed.
I. Quantification of anoikis (live/dead cells). J. Representative bright-field images of
clusters, scale bar-50µm, K. Quantification of clusters as in (J); 3-6 randomly-assigned
fields/per clone normalized to area, ≥40cells/clone. L-O. Representative flow cytometry
dot-plots and quantification of CD24/CD44/CD104 positive cells. P. Representative
images of mammospheres. Scale bar-50µm. Mammosphere quantification of Q.
Diameter, R. # mammospheres/area. One-way ANOVA, +/-S.E.M, Dunnett’s test,
ns=non-significant.
Figure 3. N-AURKA induces hypoxia in xenograft models of breast cancer. A.
Experimental design of xenograft study, n=2 clones/subline, n≥5 mice/group, n=2
experiments. B. Quantification of ultrasound-based tumor volume (mm3) plotted over
48

time. Mixed-effect model analysis. C. Representative images of gross tumor pathology,
scale bar-5mm. D. Tumor H&E images, inset-necrotic area, scale bar-1mm. E.
Quantification of necrosis/area in tumors. F. Representative tumor images of F-IHC
staining with CD31, scale bar-100µm(top image), 50µm(inset). G. Quantification of
CD31(+) staining area (%) as in (F) normalized to total area, DAPI/nuclei(blue),
CD31(white). H. Representative tumor images of F-IHC staining with anti-Pimonidazole
(Hypoxyprobe-FITC/green), scale bar-1mm(top image), 100µm(inset). I. Quantification of
Pimonidazole(+) staining area (%) as in (H) normalized to total area, DAPI/nuclei(blue).
One-way ANOVA, +/-S.E.M, Dunnett’s test, ns=non-significant.
Figure 4. N-AURKA expressing tumors are highly metastatic. A. Representative
DAB-IHC images of Lymph Node (LN) metastases stained with anti-RFP-antibody. Scale
bar-100µm. B. Representative H&E images of lung and liver metastases; femur/sternum
bone metastases stained with human-specific anti-mitochondria antibody. Metastases
outlined in black. Scale bar-50µm(lung), 200µm(liver), 500µm(bone). C. Quantification of
metastatic penetrance, as percent of mice which developed LN, lung, liver, and bone
metastases. D. Quantification of number of metastases/area of lung, liver, or bone. E.
Quantification of size of LN and lung metastases. One-way ANOVA, +/-S.E.M, Dunnett’s
test, ns=non-significant.
Figure 5. RNA-seq profile of N-AURKA cells. A. Heat-map of differentially expressed
genes (DEGs, mean values) in cells. Gene expression (n=3167) is normalized log2
counts/million. B. Principal Component Analysis of RNA-Seq libraries as in (A). C.
Volcano-plot analysis of RNAseq data as in (A) NLS-AURKA vs. control, log2 fold
changes of gene expression on the x-axis, FDR statistical significance (−log10 p-value)
on the y-axis; upregulated (red), downregulated (black) genes in NLS, all genes (blue).
Genes with at least a >1.5 fold change and FDR<0.01 are displayed. D. Visualization of
Gene Ontology terms for NLS-AURKA vs. control; up/downregulated GOterms (FDR<0.1)
are depicted as circles; the distance indicates the relationship between terms: closer
distance means higher similarity. Color and size of circles indicate significance of
differential expression of an individual GO term in log10 p-value. E. WB analysis of
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selected RNA-seq target proteins as in (A). F. Quantification of WB in (E), fold change
over control. G. GSEA comparison NLS-AURKA vs. control for selected GOterm gene
sets. H. Heat-map of HIF-dependent DEGs. I. Predicted upstream regulators: activated
(yellow), inhibited (blue) using IPA activation z-score. One-way ANOVA, +/-S.E.M,
Dunnett’s test, ns=non-significant.
Figure 6. N-AURKA binds to HIF1A/B and promotes transactivation of hypoxiaresponse genes. A. WB analysis of HIFs in cells with indicated antibodies, DMSOvehicle or DMOG for 7hr. B. Quantification of WB results as in (A), fold of change over
DMSO-control. C-D. Representative images of Immunoprecipitation/WB analysis with
indicated antibodies, WCL-whole cell lysate. E. Quantification of ChIP qPCR against
selected promoter region, normalized to total input. F. WB analysis of ChIP (before decrosslinking). G. Mass spectrometry analysis of AURKA-IP complexes: Venn diagram
displaying the numbers of proteins found in the NLS- or NES-AURKA complexes. The
850 proteins/yellow were further filtered, nuclear/blue. Pie-chart showing distribution of
N-AURKA binding partners based on functional Panther Gene Ontology terms. Tables
showing selected nuclear protein classifications for H. RNA-binding and I. DNA-binding
from PANTHER Gene Ontology. One-way ANOVA, +/-S.E.M, Dunnett’s test, ns=nonsignificant.
Figure 7. HIF1A/B is required for N-AURKA-driven invasion. A. WB analysis of HIFs
in cells as indicated, treated with siRNA: control-scr or anti-HIF1A/B. B. Quantification of
WB results in (A), fold of change over siScr. C. Individual cell movement tracking-plots
toward chemoattractant. Cell lines as indicated. Graphs of D. Total distance, E. Cell-body
directionality, F. Cell speed. G. qPCR analysis of select genes in control and NLS-AURKA
cells with siScr and siHIF1A/B, fold change over control-siScr. H. qPCR analysis of
FOXM1 in control and NLS-AURKA cells treated with siScr and siHIF1A/B, fold change
over control-siScr. I-J. qPCR analysis of FOXM1, HIF1A, and HIF1B in control and NLSAURKA cells treated with siScr and siFOXM1, fold change over control-siScr. HIF1B:
(unpaired t-test: con-Scr vs NLS-AURKA-Scr). One-way ANOVA, +/-S.E.M. Tukey’s test,
ns=non-significant.
50

Figure 8. Inhibition of N-AURKA kinase activity decreases breast cancer
metastasis. A. Experimental design of xenograft study, n=3 mice/group B. Quantification
of Fluorescent-IHC using phospho-AURKA-T288 antibody in tumors. n=50 mitoticcells/tumor. C. Quantification of final tumor volume/mm3. D. Representative H&E images
of lung metastases and DAB-IHC images of liver metastases stained with anti-RFPantibody. Metastases outlined by black line. Scale bar-50µm. E-F. Lung and liver
metastasis penetrance in mice treated with vehicle or MLN8237. G-H. Quantification of
metastases: number and area of metastases normalized to total area. One-way ANOVA,
+/-S.E.M. Tukey’s test. I. Model of Nuclear-AURKA-HIF1 mediated gene expression.
Normoxia: HIF1A is hydroxylated/ubiquitinated by PHDs/VHL resulting in degradation.
Hypoxia: low-oxygen stabilizes HIF1A leading to HIF1A/B dimerization/activation,
transactivation of hypoxia-response genes. Normoxia+N-AURKA: HIF1A/B activity is
increased leading to metastasis. MLN8237 inhibits AURKA activity decreasing
metastasis.

51

Figures

52

53

54

55

56

57

58

59

Supplementary Materials and Methods
Cell Culture, plasmids, and reagents. Cell medium, supplements were purchased
from ATCC, FBS (fetal bovine serum, VWR), Doxycycline (Sigma). MLN8237 was
purchased from Sellekchem and dissolved in 5% DMSO, 30% PEG-300, and 5%
Tween-80 in water. cDNA for human AURKA (Open Biosystems) was subcloned
(XhoI/EcoRI) into pcDNA3.1-mRFP (Invitrogen) and pLUTz-mRPF (tet-inducible)
vectors for cell culture experiments, generating pLUTz-mRFP-AURKA. To create
pLUTz-mRFP-NLS-AURKA, pmRT2 plasmid was used as an intermediate to clone a
NLS sequence (5’-CCTAAGAAGAAGCGTAAGGTC-3’) to the N-term of AURKA by
EcoRI and PstI restriction sites. A NES sequence (5’TTACAATTACCTCCTTTAGAACGTTTAACTTTA-3’) was added to the C-term of
AURKA cDNA by PCR to produce pLUTz-mRFP-NES-AURKA. The resultant plasmids
pLUTZ-NLS/NES or no-Tag-mRFP-AURKA were expressed in MDA-MB-231 and BT549 cell lines. To allow for sgRNA targeting of endogenous, but not exogenous AURKA,
site-directed mutagenesis was done on AURKA cDNA constructs to create 4 silent
mutations (MUT1, MUT2) interfering with sgRNAs targeting AURKA (sgAURKA1,
sgAURKA2) (Fig.1F outlines cell line production). Sequences for cloning primers,
mutagenesis primers, and sgRNAs are in Supplementary Table S1. pLenti PGK-V5LUC/Neo (gift from Eric Campeau (1), RRID: Addgene_21471), lentiCRISPRv2 (gift
from Feng Zhang (2), RRID: Addgene_52961), and pLUTZ-mRFP-AURKA were used to
make lentiviral particles as previously described (3). Lastly, cells were transduced with
LentiCRISPRv2-sgAURKA plasmids to knock-out endogenous AURKA. After each step
cells were selected with either zeocin (Invivogen), puromycin (Mediatech Inc), or G418
(Cellgro). Clones were analyzed by DNA sequencing and western blot to confirm
deletion of endogenous and expression of exogenous AURKA. siRNAs were introduced
via nucleofection (Amaxa) according to manufacturer’s recommendation and used in
further assays 48 hours post nucleofection after confirmation of knockdown. siRNAs
used are listed in Supplementary Table S1. For siRNA assays using siHIF1A and
siHIF1B, they were combined for all assays, denoted as siHIF1A/B.
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Tumor Micro Array and Patient Data. Immunohistochemical (IHC) procedures were
done according to the manufacturer's recommendations (US Biomax Inc.) in duplicates.
Manual scoring of staining positivity, as well as location and cell types was completed
by an independent pathologist from US Biomax, Inc. Each core was scanned by the
Aperio Scanning System (Leica Biosystems). The total number of positive cells and the
intensity of AURKA staining were computed by Aperio Image- Scope10.1 software
based on the digital images taken from each core. The de-identified patient information
for BR2082 is listed in Supplementary Table S3. Breast Cancer biopsies were collected
through the WVU Cancer Institute (IRB protocol # WVU011113) or Cooperative Human
Tissue Network (NCI) in accordance with WVU and CHTN-approved IRB protocols. The
de-identified patient information is listed in Supplementary Table S4.
Nuclear/Cytoplasmic Fractionation. 5x106 cells were lysed in PTY buffer (50 mM
HEPES, 50mM NaCl, 5mM EDTA, 1% Triton X-100, 50mM NaF) with
protease/phosphatase inhibitors (ThermoFisher) for 10 min at 4°C and centrifuged to
pellet nuclei. The supernatant was collected as the cytoplasmic fraction. The remaining
nuclei-containing pellet was washed, centrifuged, and re-suspended in PTY buffer. The
nuclei were disrupted by sonication followed by centrifugation. The resultant
supernatant was used as the nuclear fraction.
Fluorescent (F-IHC). The tissue sections were processed for fluorescent
immunohistochemistry (F-IHC) as previously described (4). IHC images were obtained
using Olympus VS120 Slide Scanner microscope with 20X U Plan S Apo/0.75 NA
objective. The images inside each data set were collected with the same microscopy
and image capture settings and the raw data were used for image quantification.
Percent staining was quantified by using area of positive stain divided by total area,
done in ImageJ software using thresholding. Integrated density was quantified using
ImageJ software. Antibodies used are listed in Supplementary Table S2.
DAB-IHC. The tissue sections were processed for immunohistochemistry (IHC) as
previously described (5). Briefly, following antigen retrieval and blocking steps, sections
were incubated in primary antibody for 60 min, followed by species appropriate
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biotinylated secondary antibodies (Biocare Medical), and then streptavidin peroxidase
(ThermoFisher). Stain was developed with 3,3′-diaminobenzidine substrate
(ThermoFisher) and sections were counterstained with hematoxylin (Biocare Medical).
As a negative control, adjacent serial sections were incubated with species appropriate
non-specific IgG (Jackson ImmunoResearch). IHC images were obtained using
Olympus VS120 Slide Scanner microscope with 10X Plan S Apo/0.40 NA objective.
Antibodies used are listed in Supplementary Table S2.
Anoikis assay. 2.5x105 cells were plated on Ultra-Low attachment plates (Corning) with
growth medium for 48 hours. Ready-Probes Cell Viability Imaging Kit (Blue/Red,
ThermoFisher) was used to detect anoikis. Labeled cells were imaged on a Leica-DMIL
microscope with a Leica-HI/PLAN I 10x/0.22 objective. Quantification was based on
Hoechst33342 (360/460nm, total) and Propidium iodide (535/617nm, dead) positivity
using ImageJ. Two independent experiments with two biological and three technical
replicates for each group with 100 cells/condition were counted in 8 random fields.
Flow cytometry analysis. Single-cell suspension of 1x106 cells in FACS staining buffer
(PBS, 0.5% BSA, 0.1% sodium azide) was blocked with 1µg anti-human IgG (Sigma) for
15 min then stained with a combination of antibodies listed in Suppl.Table S2 for 1hr.
Cells were washed, fixed with 0.4% paraformaldehyde (EMS). A minimum of 50,000
events were recorded for each subline with 2 biological clones and 2 technical
replicates. Cells were analyzed by LSR-Fortessa (BD Biosciences) and FCS-Express-6
(DeNovo) software. Cells were fist gated on FSC vs SSC and then on live cells
(Live/Dead). After gating on single stained controls, negative control (MCF7), and nostain control was finished, each sample was collected. Samples were quantified for
positive cells, negative cells, and median fluorescent intensity for CD44, CD24, and
CD104.
Immunoprecipitation (IP) assay. 106 cells were washed with Dulbecco PBS (Corning),
lysed with M-PER lysis buffer (ThermoFisher) with protease inhibitor cocktail
(ThermoFisher) and placed in 4°C for 10 min. The lysate is centrifuged for 15 min at
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15000rpm, 4°C. The whole cell lysate (WCL) supernatant is pre-cleared via incubation
with Protein A/G sepharose (GE Healthcare) rotating for 30 min at 4°C. After preclearing, beads are separated by centrifugation, 600 rpm for 5 min, 4°C and the
supernatant (300µg of protein) is used for IP of AURKA with 0.3µg of affinity purified
rabbit polyclonal anti-AURKA antibody (AurA-N, Open Biosystems, custom made using
1–126aa N-terminal fragment of AURKA) (6), conjugated to 4B sepharose or rabbit nonspecific, affinity pure IgG/protein A/G sepharose (negative control). Samples were
incubated overnight rotating at 4°C. Next, beads were washed three times with lysis
buffer supplemented with protease inhibitors followed by addition of laemmli gel-loading
dye, 10min at 100C boiling and loading on 4-12% SDS-PAGE gel (2h, 120v) and
transfer onto PVDF membrane. IPs were done with 2 clones/subline and repeated 3
times. GAPDH was used as the loading control.
Mass Spectrometry. IP samples eluted from the beads were submitted to MS Bioworks
(Ann Arbor, MI) for protein complex profiling which involved SDS-PAGE, in-gel digestion
with trypsin, and LC-MS/MS. Protein identification data was received as an excel file
and Scaffold (Proteome Software) file with contaminants and reverse hits removed.
Proteins identified were normalized to IgG control, to determine significant partners.
Protein bioinformatics was done using Gene Ontology Resource
(http://geneontology.org/). Due to usage of WCL for IP some of the NLS-AURKA
interacting proteins are cytoplasmic, and thus were excluded from further analysis.
Orthotopic xenograft model of breast cancer. Two days before cell injection, female
mice were placed on Doxycycline (Bio-Serv) diet to enable AURKA expression in
injected cells. The endpoint of study was when a tumor volume of 800mm3 was
reached. The study has been conducted with 5-10 mice/group and repeated at least
twice. MLN8237 or vehicle administration began when primary tumors reached 150–
200mm3. 20mg/kg/dose were administered via oral gavage once daily for 5 days/week
for 2 weeks and endpoint was after treatment ended. 3 mice/group in MLN8237
experiment. The organs from 3-5 mice/condition were collected, fixed in formalin, and
processed using hematoxylin/eosin staining or IHC. A WVU clinical pathologist, blinded
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to sample identity, analyzed the de-identified samples for metastatic burden. The
number/size of metastases were normalized to organ area in multiple fields of view for
each mouse.
RNA Sequencing and Bioinformatics. Total RNA was isolated from MDA-MB-231
cells expressing empty-RFP vector controls, WT-, NES- or NLS-AURKA (2 clones of
each and 2 independent experiments) using an RNeasy Mini-kit (Qiagen). RNA quality
analyzed using Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.). RNA-Seq libraries
were constructed from 500ng of total RNA using the KAPA mRNA Hyper Prep kitBiosciences with Illumina compatible adapters. The concentrations of the completed
libraries were quantified with a qubit fluorometer using high sensitivity DNA reagent.
Libraries were subsequently run on the bioanalyzer using a high sensitivity DNA chip to
determine average fragment size. Completed libraries were then pooled in equimolar
concentrations and sequenced on the HiSeq 2500 with PE50bp reads. RNA-Seq data
analysis follows the procedures established in previous publications (7-9). Briefly, RNASeq short reads were aligned to the hg38 with subread (10). The summarization of read
counts against RNA-Seq gene annotation was processed with the FeatureCounts
function implemented in the Rsubread R package (11). Differentially expressed genes
were predicted by EdgeR (12) with FDR less than 0.01 and a FC more than 2. Gene
ontology enrichment analysis was done with the online DAVID Bioinformatics Resource
(13) and visualized with REVIGO (14). Hierarchical clustering was applied to generate
heatmaps after z-normalization. The RNA-seq raw and processed files were deposited
to GEO and can be accessed at GSE154494. Processed files of comparisons with fold
change were analyzed through the use of IPA (15) (QIAGEN Inc.,
https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).” For GSEA,
comparison lists of Control/NLS and NES/NLS were used in analysis performed against
gene sets (16-18) from the MSigDb database (19, 20). The analysis was done in the
desktop GSEA software (19, 21) using 1000 phenotype permutations, and gene sets
with a nominal p value<0.05 and false discovery rate FDR <0.25 were considered
significant.
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Quantitative RT-PCR. qRT-PCR was performed using PrimeTime Gene Expression
Master-Mix (IDT #1055770) or Taqman Gene Expression Master-Mix (Applied
Biosciences #4369016) and the Applied Biosystems-7500 Fast real-time PCR-system
and software. 2 clones/subline and 2 replicates per qPCR. The relative expression of
each gene was calculated using the comparative CT values and normalized to the
housekeeping gene GAPDH or beta-actin.
Chromatin Immunoprecipitation Assay. Briefly, 5x106 of MDA-MB-231-NLS-AURKA
cells (two clones) were used for each IP. Cells were cross-linked with 1% formaldehyde,
treated with micrococcal nuclease for chromatin digestion, and briefly sonicated (3x,
20sec pulses). The 2µg of anti-AURKA (Bethyl), positive control anti-HIF1A antibodies
(Cell Signaling #5537S), or negative control (rabbit IgG) were used for
immunoprecipitation overnight. After de-crosslinking and DNA purification, the ChIP
DNA was used for quantitative-polymerase chain reaction (qPCR, IDT, PrimeTime
assays) for HRE gene promoters. Primer sequences are listed in the Supplementary
Table S6. At least 2 repeats of ChIP assay and qPCR analysis were conducted.
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Supplementary Figure Legends
Supplementary Figure 1. Nuclear AURKA is present in breast cancer metastatic cells.
Kaplan–Meier patient survival plots were generated by the Kaplan–Meier Plotter
(http://www.kmplot.com) to determine the effect of AURKA expression (microarray data Affy
ID: 208079_s_at) on the progression free survival of A. 3,951 patients with breast cancer (BC),
B. 255 patients with TNBC, C. 2,061 patients with ER+ BC. D. Representative IHC images of
breast cancer patient biopsies (IRB protocol # WVU011113) with AURKA antibody (brown,
DAB), nucleus (blue) hematoxylin. Scale bar-20µm. The de-identified tumor biopsy information
is shown in Suppl.Table S4. E. Breast cancer patient biopsies with metastases or no
metastases at collection showing analysis of spearman’s rank correlation between nuclear
AURKA positivity and metastatic outcome. The de-identified tumor biopsy information is shown
in Suppl.Table S4. F. Representative immunofluorescence images of BC cell lines and
immortalized non-tumor control (MCF10A) as indicated. Blue-DAPI/nuclei, green-AURKA
(endogenous). Scale bar-10µm. G. Correlation between presence of nuclear AURKA and
metastatic proficiency of indicated cell lines in mouse models based on published reports.
Supplementary Figure 2. Depletion of FOXM1 does not change stem cell phenotype in
NLS-AURKA cells. Median fluorescent intensity of A. CD24, ***p=0.0001, *p=0.0161 (Con vs
NLS-AURKA), B. CD44, *p=0.0492, ns=non-significant, (Con vs NLS-AURKA), C. CD104
based on flow cytometry analysis. n=2 clones/subline, n=2 replicates, *p=0.0166 (NES-AURKA
vs NLS-AURKA), one-way ANOVA, +/-S.E.M, Tukey’s test. D. Representative dot plots of flow
cytometry analysis of CD24 and CD44 in Control and NLS-AURKA cells with depletion of
FOXM1 or scramble. E. Quantification of cells from (D) positive for CD24 and CD44 gated from
live cells. n=2 clones/subline, n=2 replicates, ns=non-significant, one-way ANOVA, +/-S.E.M,
Tukey’s test. F. Representative dot plots of flow cytometry analysis of CD24 and CD104 in
Control and NLS-AURKA cells with depletion of FOXM1 or scramble. G. Quantification of cells
from (F) positive for CD24 and CD104 gated from live cells. n=2 clones/subline, n=2 replicates,
ns=non-significant, one-way ANOVA, +/-S.E.M, Tukey’s test. H. Median fluorescent intensity of
CD24, CD104, and CD44; ns=non-significant, based on flow cytometry analysis. n=2
clones/subline, n=2 replicates, one-way ANOVA, +/-S.E.M, Tukey’s test. I. Mammosphere
diameter analysis reported in relative units (RU) for Control and NLS-AURKA (2 clones) cells
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with depletion of FOXM1 or scramble. n=2 replicates, one-way ANOVA, +/-S.E.M, Tukey’s
test.
Supplementary Figure 3. Final tumor measurements. A. Final primary tumor volume (mm3),
ultrasound-based measurements, n≥5 mice in each group, 2 independent experiments, nsnon-significant, one-way ANOVA, +/-S.E.M, Dunnett’s test. B. Representative ultrasound
images of tumors at week 8, tumors outlined in yellow. C. Representative Fluorescent-IHC
images of staining with anti-Ki67 antibody, primary tumors, DAPI/nuclei (blue), Ki67 (red) scale
bar-100µm (top image, merged), 50µm (inset). D. Quantification of Ki67 positive area (%) as
in (C) normalized to total nuclei area, n≥5 tumors/subline, 2 independent experiments, ns-nonsignificant, one-way ANOVA, +/-S.E.M, Dunnett’s test. E. Quantification of Nuclei positive area
(%) as in (C) normalized to total tumor area, n≥5 tumors/subline, 2 independent experiments,
ns=non-significant, one-way ANOVA, +/-S.E.M, Dunnett’s test.
Supplementary Figure 4. Lymph node IVIS analysis. A. Representative bioluminescence
images of mice with LN metastases at 8 weeks. B. Quantification of bioluminescence plotted
as average radiance (p/s/cm2/sr), n≥5 mice/subline, *p<0.05, ns=non-significant, one-way
ANOVA, +/-S.E.M, Dunnett’s test.
Supplementary Figure 5. NLS-AURKA gene expression changes are reproduced in
BT549 and MDA-MB-231 tumors. A. Volcano plot for NLS-AURKA vs NES-AURKA
comparison with the log2 fold changes in gene expression on the x-axis and the FDR statistical
significance (−log10 p-value) on the y-axis. Red: genes up-regulated in NLS; Black: genes
down-regulated in NLS; Blue: all expressed genes. Annotated genes with at least a >1.5 fold
change and FDR<0.01 are displayed. B. Venn Diagrams of DEGs as in Fig.5A in pair-wise
comparisons of NLS-AURKA vs Control, NLS-AURKA vs NES-AURKA, and NLS-AURKA vs
WT-AURKA. C. Visualization of Gene Ontology (GO) terms representing biological processes
for NLS-AURKA vs NES-AURKA. Up- and down-regulated GOterms (FDR<0.5) are depicted
as circles; the distance between those indicates the relationship between terms: closer
distance means higher similarity. Color and size of circles indicates significance of differential
expression of an individual GO term (red low and blue high, in log10 p-value). D. Western blot
analysis of selected RNA-seq target proteins in BT-549-sublines (similarly produced as MDA75

MB-231 sublines) with indicated antibodies, tubulin- loading control. E. Quantification of
western blot as in (D) normalized to tubulin and referenced to Control (fold of change).
VEGFR-2: *p=0.029, HK1: *p=0.035, CD49f: *p=0.011, CASP3: *p=0.018. F. qPCR array
analysis of BT-549-AURKA sublines: empty vectors (Control), NLS-AURKA, NES-AURKA for
selected genes from the RNA-seq DEGs (as in Fig.5A), which are down-regulated (blue) or upregulated (red) in NLS-AURKA cells. Fold change over Control, n=2/subline, INHBB:
**p=0.002, ***p=0.008; one-way ANOVA, +/-S.E.M, Tukey’s test. ATP9A: *p=0.039; NOG:
*p=0.039, ns=non-significant, unpaired t-test two-tail (NLS vs NES). G. Heat map of a subset
of differentially (down-blue, up-red) expressed genes in MDA-MB-231-AURKA sublines which
were used in the qPCR-based analysis of MDA-MB-231-AURKA sublines-derived tumors: H.
down-regulated and I. up-regulated genes in NLS-AURKA cells and tumors. The qPCR results
normalized to house-keeping genes (actin and GAPDH) shown as fold change over Control,
n=3 tumors in each group. DEGs: HSPB8: *p=0.04, ATP9A: *p=0.021, MAPRE3: *p=0.019,
CXCR4: **p=0.0029, ADAMTS1: **p=0.0043, EHD3: *p=0.029, ns=non-significant, one-way
ANOVA, +/-S.E.M. Tukey’s test. J. Kaplan–Meier patient survival plots for BC (basal subtype)
of up-regulated hypoxia genes (from Fig.5H). K. Kaplan–Meier patient survival plots for BC of
down-regulated hypoxia genes (from Fig.5H).
Supplementary Figure 6. HIF expression in BT549 and MDA-MB-231 tumors. A. Western
blot analysis of HIFs expression with antibodies as indicated in BT-549-AURKA sublines:
empty vectors (Con), NES-AURKA (NES), NLS-AURKA (NLS), loading control- GAPDH. B.
Quantification of WB as in (A), n=2 clones/sublines, *p=0.035, ns=non-significant, one-way
ANOVA, +/-S.E.M, Tukey’s test. C. WB analysis of HIFs expression in mammary tumors
produced by MDA-MB-231 sublines as indicated using anti-HIF antibodies and GAPDH used
as loading control. D. Quantification of WB as in (C), n=3 tumors for each group, **p=0.0078,
***p=0.0006, ****p=0.0001, ns=non-significant, one-way ANOVA, +/-S.E.M, Dunnett’s test. E.
Representative images of IHC analysis of mammary tumors with HIF1A antibodies; n=3 tumors
per each subline as indicated. HIF1A (DAB/brown), nuclei (blue), scale bar-20µm.
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Supplementary Tables

Supplementary Table S1. sgRNAs, primers, and siRNAs used in this study:
Name

Forward

Reverse

AURKA-NES Insert

CTAGCAAACAGTCTTTACAATT
ACCTCCTTTAGAACGTTTAACT
TTATAGC

TCGAGCTATAAAGTTAAACGT
TCTAAAGGAGGTAATTGTAAA
GACTGTTTG

sgAURKA_1

caccgGCTTGTCTCCAGTCACAA
GC

aaacGCTTGTGACTGGAGACA
AGCc

sgAURKA_2

caccgTTACCAGGTGCCGATGG
CAG

aaacCTGCCATCGGCACCTGG
TAAc

AURKA MUT1.1

GCTTGTCTCCAGCCATAAGCC
GGTTCAG

CTGAACCGGCTTATGGCTGG
AGACAAGC

AURKA MUT1.2

GCACAAAAGCTCGTATCCAGC
CATAAGC

GCTTATGGCTGGATACGAGC
TTTTGTGC

AURKA MUT2.1

CAAGCAGCCCCTACCCTCGGC
ACCTG

CAGGTGCCGAGGGTAGGGG
CTGCTTG

AURKA MUT2.2

ACCCTCGGCACCGGAGAATAA
TCCTGAGG

CCTCAGGATTATTCTCCGGT
GCCGAGGGT

Source

Catalog #

Dharmacon

L-004018-00-0010

Dharmacon

L-007207-00-0010

siRNAs used in this study:
siRNA
SMARTpool:
TARGETplus HIF1A

ON-

SMARTpool:
TARGETplus ARNT

ON-

SMARTpool:
TARGETplus FOXM1

ON-

Negative Control siRNA

Dharmacon

L-009762-00-0005
SN-1005

Bioneer
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Supplementary Table S2. Antibodies used in this
study:
Target

Company and Cat#

Western
IHC
Blot

IF

Aurora Kinase A

BD Biosciences
#610939

1:500

1:100
F-IHC
1:100,
DAB
1:135

Aurora Kinase A

Bethyl IHC-00062

Aurora Kinase A

Cell Signaling #91590 1:1000

Phospho-Aurora Kinase A
(T288)

Bethyl #IHC-00067

RFP

Rockland #600-401379

1:2000

DAB
1:200

HIF1A

Bethyl #A700-001

1:1000

DAB
1:50

HIF1B

Cell Signaling #3537

1:1000

HIF2A

Novus #NB100-122

1:1000

HIF2B
GAPDH
Gamma-tubulin
Lamin A/C
Alpha/beta-Tubulin
Tubulin-alpha

Proteintech #12810-1
Santa Cruz #47724
Santa Cruz #7396
Bethyl #A303-430
Cell Signaling #2148
Sigma #T9026

1:500
1:1000
1:1000
1:1000
1:1000
1:1000

Human Mitochondria

Millipore #MAB1273

DAB
1:150

CD31

Cell Signaling
#3528S

F-IHC
1:100

Pimonidazole-FITC (clone
4.3.11.3)

Hypoxyprobe
#HP FITC MAb-1

F-IHC
1:50

Ki67-555

BD Biosciences
#558617

F-IHC
1:100

VEGFR-2
PDK1
Caspase-3
KISS1

Santa Cruz #6251
Cell Signaling #3062
Santa Cruz #56053
Proteintech #18375-1

1:1000
1:2000
1:1000
1:500

DLC1

BD Biosciences
#612-020

1:500

BCL2

Millipore #A1784

1:1000

F-IHC
1:100
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DAB
1:1000

1:500

Flow
Cytometry

CD49f
HK1
HnRNPk
Histone H2B
Histone H3

Bethyl #A303-682A
Cell Signaling #2024
Santa Cruz #28380
Cell Signaling
#3094S
Santa Cruz #515808
Cell Signaling #14269

Peroxidase AffiniPure
Donkey Anti-Rabbit IgG
(H+L)

Jackson
ImmunoResearch
Labs #711-035-152

1:10000

Peroxidase AffiniPure
Donkey Anti-Mouse IgG
(H+L)

Jackson
ImmunoResearch
Labs #715-035-150

1:10000

Live/Dead Near-IR

Thermo Scientific
#L10119

Aurora Kinase B

EpCam-VioBue
CD44-FITC
CD24-APC
CD104-PE-Vio770

1:1000
1:2000
1:1000
1:1000
1:1000
1:1000

1µl/1x106
cells

Miltenyi #130-097324
Miltenyi #130-115867
Miltenyi #130-112657
Miltenyi #130-101441

1:50
1:50
1:66
1:50

Anti-Rabbit-488

Jackson
ImmunoResearch
Labs #711-545-152

F-IHC
1:200

1:1000

Anti-Mouse-488

Jackson
ImmunoResearch
Labs # 715-545-150

F-IHC
1:200

1:1000

Anti-Rabbit-555

Invitrogen #A31572

F-IHC
1:200

1:1000

Anti-Mouse-555

Invitrogen #A31570

F-IHC
1:200

1:1000

Anti-Mouse-647

Jackson
ImmunoResearch
Labs #715-605-150

F-IHC
1:200

1:1000

Anti-Human IgG

Sigma #I4506

1ug
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Supplementary Table S3. Tumor Micro Array.
Position Age Sex Organ
Lymph
A1
40
F
node
Lymph
A2
55
F
node
Lymph
A3
56
F
node
Lymph
A5
57
F
node
Lymph
A6
56
F
node
Lymph
A7
42
F
node
Lymph
A8
49
F
node
Lymph
A9
66
F
node
Lymph
A10
38
F
node
Lymph
A11
51
F
node
Lymph
A12
39
F
node
Lymph
A13
53
F
node
Lymph
A15
44
F
node
Lymph
A16
55
F
node
Lymph
B1
47
F
node
Lymph
B2
39
F
node
Lymph
B3
52
F
node
Lymph
B4
60
F
node
Lymph
B5
52
F
node
Lymph
B6
28
F
node
Lymph
B7
58
F
node
Lymph
B8
42
F
node
Lymph
B9
42
F
node

Pathology diagnosis
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma of No. 81
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
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Grade Type
2

metastasis

1

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

1

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

1

metastasis

2

metastasis

2

metastasis

2

metastasis

3

metastasis

2

metastasis

2

metastasis

2

metastasis

B10

48

F

B11

80

F

B12

59

F

B13

60

F

B14

28

F

B15

55

F

B16

62

F

C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
D1
D2
D3
D4
D5
D6
D7
D8
D9
D11
D12
D13
D14
D15

30
44
37
61
50
39
42
41
65
63
71
43
54
38
47
44
53
42
59
38
43
48
41
38
45
41
32
62
50
68

F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F

Lymph
node
Lymph
node
Lymph
node
Lymph
node
Lymph
node
Lymph
node
Lymph
node
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast

Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma of No. 79
Metastatic invasive ductal
carcinoma
Metastatic invasive ductal
carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma

81

2

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

2

metastasis

1
1
1
2
2
2
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant

D16
E1
E2
E3
E4
E5
E6
E8
E9
E10
E11
E12
E13
E14
E15
E16
F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
F13
F14
F15
F16
G2
G3
G4
G5
G7
G8
G9
G10
G11
G12

44
45
29
67
50
54
35
29
55
50
43
43
45
50
28
55
52
38
49
46
62
42
53
45
32
29
65
64
63
51
56
62
32
55
53
50
47
51
69
70
59
35

F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F

Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast

Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive ductal carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
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2
2
2
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
2
2
2
2
2
-

malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant

G13
G14
G15
G16
H1
H2
H3
H4
H5
H6
H7
H8
H9
H10
H11
H12
H13
H14
H15
I1
I2
I3

38
42
52
41
47
50
66
46
48
38
45
52
45
52
41
37
48
47
49
38
42
27

F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F

Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast

Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma (sparse)
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma (sparse)
Invasive lobular carcinoma
Invasive lobular carcinoma
Invasive lobular carcinoma (sparse)
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Squamous cell carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma

1--2
2
2
2
-

malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant

I5

41

F

Breast

Intraductal carcinoma (hyperplasia
of breast duct)

-

malignant

I6
I7
I8
I9

43
32
58
67

F
F
F
F

Breast
Breast
Breast
Breast

Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma

-

malignant
malignant
malignant
malignant

I11

49

F

Breast

Intraductal carcinoma with early
infiltration

-

malignant

I12
I13
I14
I15
J1
J2
J3
J4
J5
J6
J7

32
81
39
43
46
60
64
40
48
54
49

F
F
F
F
F
F
F
F
F
F
F

Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast

Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Intraductal carcinoma
Lobular carcinoma in situ
Lobular carcinoma in situ
Lobular carcinoma in situ

-

malignant
malignant
malignant
malignant
malignant
malignant
malignant
malignant
In Situ
In Situ
In Situ
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J8

62

F

Breast

Lobular carcinoma in situ (fibrous
tissue)

-

In Situ

J9
J10
J11
J12
J13
J14
J15
J16
K1
K2
K3
K4

44
27
23
23
19
23
42
25
48
43
41
34

F
F
F
F
F
F
F
F
F
F
F
F

Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast

Fibroadenoma
Fibroadenoma
Fibroadenoma
Fibroadenoma
Fibroadenoma
Fibroadenoma
Fibroadenoma
Fibroadenoma
Mild hyperplasia of breast duct
Adenosis with hyperplasia of duct
Adenosis with hyperplasia of duct
Mild hyperplasia of breast duct

-

benign
benign
benign
benign
benign
benign
benign
benign
hyperplasia
hyperplasia
hyperplasia
hyperplasia

K5

40

F

Breast

Atypical hyperplasia in duct (grade
II)

-

hyperplasia

K6

76

F

Breast

Hyperplasia (fibrofatty tissue)

-

hyperplasia

K8

37

F

Breast

Adenosis with mild hyperplasia of
duct

-

hyperplasia

K9

45

F

Breast

Adenosis with mild hyperplasia of
duct

-

hyperplasia

K12

45

F

Breast

Atypical hyperplasia of duct (grade
II-III)

-

hyperplasia

K13
K14
K15
L1
L2
L3
L4
L5
L6
L7
L8
L9
L10
L11

40
22
28
61
28
55
26
78
46
28
10
45
57
33

F
F
F
F
F
F
F
F
F
F
F
F
F
F

Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast

Cyclomastopathy
Cyclomastopathy
Cyclomastopathy (sparse)
Plasma cell mastitis
Plasma cell mastitis
Plasma cell mastitis
Plasma cell mastitis
Plasma cell mastitis
Plasma cell mastitis
Chronic inflammation
Acute mastitis
Mild chronic inflammation
Mild chronic inflammation
Mild chronic inflammation

-

hyperplasia
hyperplasia
hyperplasia
inflammation
inflammation
inflammation
inflammation
inflammation
inflammation
inflammation
inflammation
inflammation
inflammation
inflammation

L12

39

F

Breast

Chronic inflammation of fibrous
tissue

-

inflammation

L13
L14

67
40

F
F

Breast
Breast

Granulomatous mastitis
Chronic inflammation

-

inflammation
inflammation
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L16

44

F

Breast

M2

31

F

Breast

M3

45

F

Breast

M4

53

F

Breast

M6

35

F

Breast

M10

46

F

Breast

M11
M13

15
21

F
F

Breast
Breast

M14

35

F

Breast

M15

19

F

Breast

Plasma cell mastitis with ductal
ectasia
Cancer adjacent normal breast
tissue (cyclomastopathy)
Cancer adjacent normal breast
tissue
Cancer adjacent normal breast
tissue
Cancer adjacent normal breast
tissue
Cancer adjacent normal breast
tissue
Normal breast tissue
Normal breast tissue
Normal breast tissue (with mild
ductal ectasia)
Normal breast tissue (fibrous
tissue)
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-

inflammation

-

NAT

-

NAT

-

NAT

-

NAT

-

NAT

-

normal
normal

-

normal

-

normal

Supplementary Table S5. qPCR
assays:
Custom 96-well qPCR plates from Thermo scientific:
Gene
name
FGF5
ACTB
MCTP2
FBXL7
RHOJ
HLADRB1
NRXN3
SAMSN1
HMGN5
ESM1
PARP15
ELMO1
GCKR
ANO5
FREM2
NRK
HS6ST2
ADAMTS
1
ARAP2
NAP1L2
ENG
KISS1
MYCT1
EPHA7
CADM2
ROBO2
LPAR3
TNFRSF
11B
EHD3
IL1A
SNCAIP
F2RL2
CHRDL1
DOCK8
POU3F2

Assay catalog #
Hs03676587_s1
Hs99999903_m1
Hs01071657_m1
Hs00202348_m1
Hs01112007_m1
Hs04192464_mH
Hs01028186_m1
Hs01090844_m1
Hs04999451_m1
Hs00199831_m1
Hs00403748_m1
Hs00404992_m1
Hs00386984_m1
Hs01381106_m1
Hs01388268_m1
Hs00872692_m1
Hs02925656_m1
Hs00199608_m1
Hs00367362_m1
Hs01114608_s1
Hs00923996_m1
Hs00158486_m1
Hs00228305_m1
Hs01033006_m1
Hs01549516_m1
Hs00326067_m1
Hs00173857_m1
Hs00900358_m1
Hs00997783_mH
Hs00174092_m1
Hs00917423_m1
Hs00187982_m1
Hs01035484_m1
Hs00298892_m1
Hs00271595_s1
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MMP1
WT1
SELL
RGS4
DHH
FNDC4
CCDC12
0
HIST1H1
C
PRKCQ
FGFR4
FZD8
SEMA6A
OR2B6
KDR
ISYNA1
NRG2
TRIL
IL17D
SFRP1
G0S2
SIX2
GRB14
NOG
PCDHB6
STOX1
RNF128
RCAN2
MLLT11
TMEFF1
CXCR4
CST7
INHBB
EREG
EYA4
ATP9A
DLC1
GPX7
HSPB8
CNKSR1
KRT83
ABCG1

Hs00899658_m1
Hs01103751_m1
Hs01046459_m1
Hs01111690_g1
Hs00368306_m1
Hs01100278_g1
Hs01092013_m1
Hs00271185_s1
Hs00234709_m1
Hs01106908_m1
Hs00259040_s1
Hs00221174_m1
Hs01649949_s1
Hs00911700_m1
Hs01126940_gH
Hs00993399_m1
Hs04188203_s1
Hs00370528_m1
Hs00610060_m1
Hs00274783_s1
Hs00232731_m1
Hs00182949_m1
Hs00271352_s1
Hs00251789_s1
Hs03645108_m1
Hs00226053_m1
Hs00195165_m1
Hs05017984_s1
Hs00902905_m1
Hs00607978_s1
Hs00175361_m1
Hs00173582_m1
Hs00914313_m1
Hs01012399_m1
Hs00391058_m1
Hs00183436_m1
Hs00210410_m1
Hs00205056_m1
Hs00906471_m1
Hs05049821_s1
Hs00245154_m1
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NKX1-2
GSTP1
MAP1LC
3A
ID1
TCEA2
LAMB1
PPP1R3
C
MAPRE3
FAM83B
ACTA2
TRPM6
B2M
SLC2A4
MEX3A
MYB
PTPRQ
MALT1
NEGR1
TNFRSF
1B

Hs01392360_m1
Hs00943350_g1
Hs01076567_g1
Hs03676575_s1
Hs00920170_m1
Hs01055960_m1
Hs01921501_s1
Hs00202414_m1
Hs00289694_m1
Hs00426835_g1
Hs01019356_m1
Hs99999907_m1
Hs00168966_m1
Hs00863536_m1
Hs00920556_m1
Hs01386285_m1
Hs01120060_m1
Hs02387573_m1
Hs00961750_m1

PrimeTime assays from IDT Technologies:
Gene
name
NOS3
S100A4
ITGA6
PDGFB
MMP1
ADM
WT1
HIF1A
ARNT2
EPAS1
SLC2A4
KDR
CXCR4
ANGPT1
ARNT
ACTB

Assay catalog #
Hs.PT.58.21447620
Hs.PT.58.39700608
Hs.PT.58.453862
Hs.PT.58.45327803
Hs.PT.58.38692586
Hs.PT.56a.25211580.g
Hs.PT.58.22568369
Hs.PT.58.534274
Hs.PT.58.783416
Hs.PT.58.2273374
Hs.PT.58.2557238
Hs.PT.58.3285240
Hs.PT.58.22298491
Hs.PT.56a.761468
Hs.PT.56a.807676.g
Hs.PT.39a.22214847
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Name

Forward

Reverse

Probe

GAPDH

CTTTGGTATCGTGGAAG
GACTC

GTAGAGGCAGGGATGA
TGTTC

/56-FAM/CGG
GAA
ACT
/ZEN/GTG GCG TGA TGG
/3IABkFQ/
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Supplementary Table S6. ChIP qPCR primers:
Name

Forward

Reverse

Probe

CXC
R4
HRE

GGGCCGAGAAACTG
CGT

GGGATCGTGTGTAG
AGTGCAG

/56FAM/AAATGGTCC/ZEN/CGAGGAGAG
GGATTG/3IABkFQ/

ITGA
6
HRE

AGTAAAGTCTCCCTC
GCTCTGT

TCTCCAGCTGCCCG
GTA

/56FAM/ACTCGGCAA/ZEN/CCACAATTCT
GTCCA/3IABkFQ/

EPO
HRE

GGCTCTGTCCCACT
CCT

GCGTAGGCAGAGCT
TGTG

/56FAM/TGTGTGAGA/ZEN/CAGCACGTAG
GGC/3IABkFQ/

FOX
M1
prom
oter

ACCGGAGCTTTCAG
TTTGT

GATTGGCGACGTTC
CGT

/56-FAM/TCCGCTGTT/ZEN/TGA
AATTGGCGCC/3IABkFQ/
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CHAPTER 3: General Discussion
As mentioned in Chapter 1, AURKA has many functions in cancer progression and
is a prognostic factor for worse survival in patients. Recently, the separation of AURKA's
cytoplasmic and nuclear functions has come of interest. Most research focuses on
deciphering AURKA's functions regardless of localization and under the assumption that
it is cytoplasmic; however, identifying AURKA in the nucleus brought to light the significant
differences in roles cytoplasmic vs. nuclear pools of AURKA play in cancer. Similar to the
well-known tumor-suppressor - p53, which was initially identified as an oncogene,
AURKA's oncogenic potential seems to be primarily driven by its nuclear pool. At the
same time, cytoplasmic AURKA has limited oncogenic potential or even functions as a
suppressor. The long-term goal of this study is to understand nuclear AURKA's function
in tumorigenesis with a specific focus on metastasis. This chapter will discuss the main
findings, differences in nuclear AURKA models, and future directions for studying nuclear
AURKA.
In Chapter 2, this study tests the impact of nuclear AURKA on metastasis. We
report, for the first time, that nuclear AURKA promotes metastasis. This conclusion is
supported by the observation that the number of nuclear AURKA positive cells
significantly increases during cancer progression from primary breast tumor to distant
metastases; and there is a strong correlation between nuclear AURKA accumulation with
more aggressive subtypes and metastases (Chapter 2, Fig.1A-C and Suppl.Fig1E). The
next step would be to correlate nuclear AURKA presence with BC survival in patients. We
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predict that nuclear AURKA will be indicative of worse overall survival for breast cancer
patients.
The model we created to test the cytoplasmic and nuclear AURKA function
completely separates AURKA into those compartments. This was done by using an NES(nuclear exclusion signal) and NLS- (nuclear localization signal) tagged exogenous
AURKA combined with a knockout of the endogenous AURKA to produce cells with a
single compartment-restricted AURKA (Chapter 2, Fig.1F-H). These cells were used in in
vitro assays for proliferation, invasion, and stemness. The resulting NLS-AURKA cells
show increased invasion and stemness capabilities without changes in proliferation. Both
invasion and stemness capabilities are involved in the metastatic cascade. It was
previously reported that AURKA promotes invasion and migration as reviewed in Chapter
1; however, these effects were attributed to cytoplasmic AURKA. No other studies have
been published on nuclear AURKA-driven function in regulating invasion and migration,
except our research in Chapter 2. Based on RNA-seq findings, NLS-AURKA cells show
upregulation of key cytoskeleton (RHOJ, ARHGAP22, ARHGAP24, ELMO1, DEF6),
adhesion (CADM2, SELL, ITGA6), matrix-degrading (ADAMTS5, ADAMTS1, MMP1,
MMP14), and tight junction (CLDN4, CLDN11, CLDN12, CLDN23) proteins, which may
explain the increase in invasion (Chapter 2, Fig.5). Also, due to the morphology
differences in NLS-AURKA cells (smaller nuclei and more round), this is indicative of an
amoeboid morphology (1) (Chapter 2, Fig.2B-D). The amoeboid morphology and smaller
size support the ability of cells to move throughout a constricted environment (2). Due to
the morphology changes and differences in expression of genes involved with migration,
this would warrant further study of these pathways in NLS-AURKA cells.
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In breast cancer, it has been reported that AURKA overexpression leads to
increased stemness, noted by increased CD24-/CD44+ cell population and the ability to
form mammospheres (3, 4). In these models, using fractionation of the AURKA
overexpressed cells, AURKA is present in both the cytoplasm and nucleus, compared to
normal (3). Also, when AURKA is excluded from the cytoplasm, the stem cell potential
decreases, suggesting that nuclear AURKA is responsible for the increased stemness
(3). Our model agrees with these conclusions that nuclear AURKA increases stemness.
The NLS-AURKA increases the number of CD24-/CD44+ cells and their ability to form
mammospheres, compared to control and NES-AURKA cells (Chapter 2, Fig.2L-R). A
previous report by Yang et al. showed that the FOXM1/AURKA complex contributes to
regulating the self-renewal of breast cancer stem cells (4). In our model, the depletion of
FOXM1 was insufficient to change the expression of the stem cell markers or
mammosphere formation (Chapter 2, Suppl.Fig.2D-I). Based on our findings, this activity
of nuclear AURKA is mediated, at least partly, by activation of HIF1A/B, which in turn may
upregulate FOXM1 (Chapter 2, Fig.7H-J). These findings differ from previously published
reports, using either an overexpression system (4) or NES-AURKA inducible system (3).
Neither of those modeling approaches allows gauging nuclear AURKA specific function
directly. The overexpression system shows increased AURKA protein levels in both
cytoplasmic and nuclear compartments (3, 4). This is not a clean system as functions of
cytoplasmic AURKA will be increased.
The role of nuclear AURKA in metastasis is further supported by the increased
metastatic dissemination/colonization at multiple distant organs in an orthotopic breast
cancer mouse model, upon experimentally targeting AURKA to the nucleus (NLS93

AURKA) (Chapter 2, Fig.4). The metastatic penetrance of NLS-AURKA cells is 100% in
the lungs, lymph node, liver, and bone. Earlier studies showed that metastatic seeding in
the bone and liver required multiple rounds of injection to select metastatic cells (5, 6). In
our model, the bone and liver metastases were achieved without prior enrichment of cells,
suggesting that disseminating cells were selected for the presence of nuclear AURKA.
Furthermore, nuclear AURKA cells show upregulation of genes that promote bone
metastasis, including ADAMST1, FGF5, FST, CXCR4, IL-11, MMP1 (5). The metastatic
gene signature and increased metastatic penetrance in multiple organs suggest that
nuclear AURKA is a key driver of an aggressive, metastatic phenotype. Note that tumor
cells with cytoplasmic AURKA, which is found in all normal, non-transformed cells, have
limited to no metastatic capacity without impacting cell growth/proliferation (Chapter 2,
Fig.2A and Fig.4).
By integrating global gene expression and computational analyses, we found that
nuclear localization of AURKA leads to significant changes in expression of over 3,000
genes involved in the regulation of hypoxia, transcription, metastasis, and other cancerrelated pathways (Chapter 2, Fig.5 and Suppl.Fig.5). It is well-established that hypoxia is
an inducer of invasion, stemness, and metastasis (7, 8), but the role of nuclear AURKA
in the activation of hypoxia signaling is currently unknown. Our findings show that nuclear
AURKA is a potent inducer of the hypoxia-response gene signature in vitro and in vivo
(Chapter 2, Fig.6 and Suppl.Fig.6). Hypoxia signaling is primarily driven by hypoxiainducible factors (HIFs), which include oxygen-sensitive HIF-A subunits (HIF1A,
HIF2A/EPAS1) and oxygen-independent HIF-B subunits (HIF1B/ARNT, HIF2B/ARNT2).
The activation/expression of HIF-1A at diagnosis is predictive of early relapse and
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metastasis and correlates with poor clinical outcomes in human breast cancer (9-11) and
distant metastasis-free survival (12).
An enrichment of hypoxia response genes (Chapter 2, Fig.5H) was observed in
nuclear AURKA expressing cells and tumors without an increase in HIF1A or HIF2A
(Chapter 2, Fig.6A-B and Suppl.Fig.6C-E), suggesting HIF1/2A transcriptional activity
was elevated instead, potentially via recruitment/retention on the DNA. The AURKA-ChIP
complex analysis and qPCR support the notion that AURKA is binding to HRE-containing
promoters similarly to HIF1B and interacts with previously documented partners like
hnRNPk (Chapter 2, Fig.6E-I). These changes are reported under normoxic conditions in
metastatic cells and could be further induced under hypoxia. This similar phenotype was
observed in other breast cancer models (13). Nuclear AURKA gene expression changes
show metabolic reprogramming (HK1/2), angiogenesis (ADM, ANGPT1, EDN1, FECH),
invasion (CXCR4, LOX, MMP1, MMP14, ITGA6, CSRP2), and proliferation (ENG, WT1,
CCND1) being the most upregulated. The nuclear AURKA-driven hypoxia gene signature
mainly contains genes driven by HIF1A (HK2, END1, VIM, CSRP2) or HIF1/2A (CCND1,
MMP14, ITGA6, ANGPT1, ADM, LOX, CXCR4). Interestingly, in DMOG-treated NLSAURKA cells, only HIF1A was upregulated. Note that not all genes previously connected
to hypoxia were upregulated. Some canonical HIF1A-induced genes such as PDK1,
PFKP, SNAI1, and NOS3 were downregulated compared to empty-vector control,
suggesting the involvement of additional cofactors affecting transcription besides just the
HRE-driven mechanism (Chapter 2, Fig.5I). This has been demonstrated for several other
transcription factors, including Sp1(14), AP1-GATA2-NF1(15), Erg1-C/EBPα(16), Sp1HNF4(17), ETS1(18), STAT3(19), and Myc(20). The ability of other transcriptional
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activators to enhance hypoxia gene transcription in cooperation with HIF1A or
independently of HIF1A suggests the complexity of expression of HIF target genes.
Depletion of HIF1A/B in nuclear AURKA cells led to a reduction in migration/invasion and
expression of the key hypoxia signature genes, suggesting that this metastasis-driving
activity of AURKA is HIF1 dependent (Chapter 2, Fig.7A-G).
HIF-dependent transactivation requires other cofactors, including CBP/P300,
general transcription factors in assembling the pre-initiation complex (PIC), the RNAPII
complex, and chromatin remodelers (21). Evidence shows that HIF target genes are in a
paused state of transcription in normoxia conditions, which already contains the RNAPII
complex with other transcription cofactors, and is preferred to HIF1α binding (22). With
the reports of several other transcription factors enhancing hypoxia-responsive genes,
we hypothesize that nuclear AURKA acts as a transcriptional activator and may reduce
the pausing of RNAPII complex and cofactor machinery in a normoxia setting. The LCMS/MS analysis of the AURKA-complex shows p300/CBP and RNAPII complex proteins
(RPB1, RPB2, RPABC1), thus supporting the role of nuclear AURKA in the regulation of
transcription (Chapter 2, Fig.6G-I). Interestingly, LC-MS/MS analysis also revealed other
members of the super elongation complex (SEC) (23) interacting with AURKA, including
CDK9, MEPCE, TRIM28, PPM1G, and HEXI1. These findings support that AURKA being
in the nucleus is interacting with RNAPII complex and the SEC. These findings are in
agreement with the previous reports showing AURKA binding to the MYC promoter via
interaction with hnRNPk increasing MYC transcription (3). In concordance with this report,
we show that nuclear AURKA binds to chromatin complexes that contain hnRNPk
(Chapter 2, Fig.6F,H). The global ChIP-seq analysis of AURKA has not been reported;
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therefore, this is a future direction to determine potential transcriptional targets of nuclear
AURKA.
Previously it was shown that transactivation capabilities of nuclear AURKA do not
require kinase activity. Our previous reports and the current study show that inhibiting
AURKA, including nuclear kinase activity, leads to a significant decrease in metastatic
burden (Chapter 2, Fig.8). Interestingly, the kinase activity was not required for
dissemination but was critical for colonization of distant organs, suggesting a differential
effect of kinase activity on different steps in the metastatic cascade. Combining AURKA
inhibitors with HIF-targeting compounds might prove to be even more beneficial in
preventing and treating metastatic cancer. Previous studies have shown the importance
of AURKA inhibitors in decreasing tumors and metastasis (3, 24). Our data clearly shows
the importance of nuclear AURKA in metastasis, but further research is needed to
determine its role in regulating global transcription changes. A better understanding of the
function of nuclear AURKA may implicate the discovery of new biomarkers for metastatic
disease and potential therapeutic targets.

Future Directions
Due to the profound gene expression changes inflicted by nuclear AURKA, there
are many opportunities for future research to determine the molecular mechanisms of
these effects. The previous work (3, 4, 25) and our work (Chapter 2) discovering
transactivation capabilities of AURKA open a new chapter in AURKA biology related to
the regulation of transcription (Figure 1). The global ChIP-seq analysis of NLS-AURKA
cells compared to NES-AURKA and controls would identify specific promoter regions and
genes where AURKA is bound. The mapping of AURKA-driven genes will lay a foundation
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for deciphering novel metastasis-driving genes that AURKA regulates directly or
indirectly. The results will also assist in defining new AURKA binding partners involved in
transcription control and/or chromatin modification. The knockdown experiments of these
transcription factors, similar to siHIF experiments done in Chapter 2, will allow us to verify
their role on AURKA-driven metastatic cascade.
The kinase activity of nuclear AURKA is another area of interest that is still not fully
understood. Using AURKA inhibitors, it was shown that nuclear AURKA transcriptionally
activates Myc and FOXM1 in a kinase-independent manner (3, 4). However, xenograft
experiments with AURKA inhibitors show kinase function is essential for tumor
progression. Using a breast cancer xenograft model in the flank, treatment with AURKA
inhibitor led to decreased tumor growth (3, 4). From our orthotopic xenograft in Chapter
2, the kinase activity of NLS-AURKA is vital for metastatic colonization, showing
significantly decreased metastases with AURKA inhibitor (MLN8237) treatment. This
suggests that kinase activity of nuclear AURKA may be necessary for specific steps of
tumor progression and metastasis via its effects on the downstream effector proteins, but
may not be needed for its transcriptional functions. Future experiments to determine if
kinase activity is required include treating cells with MLN8237 and doing qPCR, RNAseq, ChIP-seq, and immunoprecipitation combined with Mass Spec analysis of protein
phosphorylation changes. These techniques will allow us to see global changes that may
occur when we inhibit kinase function, both transcriptionally and protein-protein
interactions. Experiments with MLN8237 can also be done with in vitro 3D invasion
assays to look at earlier metastasis stages. It remains undetermined if the nuclear
AURKA-HIF1 axis of transcriptional changes depends on kinase activity or if the HIF98

dependent function is AURKA phosphorylation-dependent. Studies with MLN8237 in our
model will need to be conducted to answer these questions.
Another area of further research would be the possible effects of nuclear AURKA
on chromatin dynamics. In our study, in NLS-AURKA cells, we observed the DNA
compaction to be different than NES-AURKA and control cells, and we also quantified
nuclei size to be smaller in NLS-AURKA cells. This could suggest some chromatin
remodeling. Supplementing these observations with high-resolution 3D microscopy of the
DNA would be an interesting future direction (26). The other data to support the possible
effects of AURKA on chromatin comes from our ChIP-WB and the Mass Spectrometry
data. The western blot analysis of the ChIP complex precipitated with anti-AURKA
antibodies detected multiple proteins, including Histone H3 and Histone H2B (Chapter 2,
Fig.6F), suggesting that nuclear AURKA is either directly or indirectly bound to these
histone subunits. The Mass Spectrometry analysis of the AURKA immunoprecipitated
complex from NLS-AURKA cells identified the following chromatin modifiers RB, PAF1,
SETB1, TRIM28, RBBP7, and more, suggesting a potential role of AURKA in the
regulation of chromatin dynamics.
Another major interest is the mechanism controlling subcellular localization of
AURKA. The only research done on nuclear AURKA localization is identifying the protein
region in AURKA that localizes it into the nucleus (amino acids 333-383) (3). There is no
identifiable NLS sequence present, but when this region of AURKA protein is deleted, its
nuclear localization is lost. These findings suggest that a protein interaction in this region
might drive localization. Even though we have done a Mass Spectrometry assessment of
AURKA immunoprecipitated complex, this was done with whole-cell lysates, limiting our
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ability to detect potential transport proteins. A cleaner experiment would be to fractionate
the cells into cytoplasmic and nuclear compartments and map interactors. We could then
identify proteins that could be bringing AURKA into the nucleus and do knockdowns to
look at AURKA localization.
Our study in Chapter 2 opens up many areas of future studies for nuclear AURKA
functions in gene regulation and binding partners. The global analyses of DNA structure,
binding partners, chromatin modifications will help identify new molecular events and
processes that AURKA regulates in the nucleus which affect metastasis. The results will
help us understand the bigger picture of nuclear AURKA driven biology and how it impacts
metastasis, leading to discoveries on how to inhibit those functions and prevent/cure
metastasis.

Figure 1. Known Nuclear AURKA Functions. A) Nuclear AURKA and HnRNPk interact,
and AURKA transactivates MYC leading to an increased number of breast cancer stem
cells. MYC transactivation is kinase-independent, but the treatment with MLN8237 leads
to decreased tumor volume. B) Nuclear AURKA transactivates FOXM1 leading to an
increased number of breast cancer stem cells. The transactivation of FOXM1 is kinaseindependent, but the treatment with MLN8237 leads to decreased tumor volume. C)
Nuclear AURKA transactivates HIF target genes via interaction with HIFs and cofactors
P300/CBP. It is not known if this transcriptional regulation is kinase-dependent. Treatment
of MLN8237 leads to decreased metastasis.
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